Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects
Phase: PHASE1
Conditions: Healthy
Sponsor: Eli Lilly and Company

 
 
Protocol I8F-MC-GPGE(a) 
 
 
Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in 
Healthy Subjects 
 
 
NCT03375463  
 
 
Approval Date: 23-Jan-2018 
 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 1
LY3298176
Protocol I8F-MC-GPGE(a)
Pharmacokinetics, Safety, and Tolerability of a Solution 
Formulation of LY3298176 in Healthy Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY3298176, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities:  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3298176
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly:  01-Sep-
2017
Amendment (a) Electronically Signed and Approved by Lilly on date provided below:
Approval Date: 23-Jan-2018 GMT

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 2
LY3298176
Table of Contents
Section
Page
Protocol I8F-MC-GPGE Pharmacokinetics, Safety, and Tolerability of a 
Solution Formulation of LY3298176 in Healthy Subjects....................................................1
Table of Contents........................................................................................................................2
1.
Protocol Synopsis................................................................................................................7
2.
Schedule of Activities .........................................................................................................9
2.1.
Study Schedule Protocol I8F-MC-GPGE, Part A..........................................................10
2.2.
Study Schedule Protocol I8F-MC-GPGE, Part B..........................................................14
2.3.
Study Schedule Protocol I8F-MC-GPGE Part C...........................................................17
3.
Introduction ......................................................................................................................20
3.1.
Study Rationale............................................................................................................20
3.2.
Background..................................................................................................................20
3.3.
Benefit/Risk Assessment..............................................................................................21
4.
Objectives and Endpoints..................................................................................................22
5.
Study Design.....................................................................................................................23
5.1.
Overall Design .............................................................................................................23
5.2.
Number of Participants.................................................................................................25
5.3.
End of Study Definition ...............................................................................................25
5.4.
Scientific Rationale for Study Design...........................................................................25
5.5.
Dose Justification.........................................................................................................25
5.5.1.
Part A...................................................................................................................25
5.5.2.
Part B...................................................................................................................25
5.5.3.
Part C...................................................................................................................26
6.
Study Population...............................................................................................................27
6.1.
Inclusion Criteria..........................................................................................................27
6.2.
Exclusion Criteria ........................................................................................................28
6.2.1.
Rationale for Exclusion of Certain Study Candidates ...........................................30
6.3.
Lifestyle and/or Dietary Requirements .........................................................................30
6.3.1.
Meals and Dietary Restrictions.............................................................................30
6.3.2.
Caffeine, Alcohol, and Tobacco ...........................................................................30
6.3.3.
Activity................................................................................................................30
6.4.
Screen Failures.............................................................................................................30
7.
Treatment..........................................................................................................................31
7.1.
Treatment Administered...............................................................................................31
7.1.1.
LY3298176 for Injection......................................................................................31

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 3
LY3298176
7.1.2.
LY3298176 Solution Formulation Injection .........................................................31
7.2.
Method of Treatment Assignment ................................................................................32
7.2.1.
Selection and Timing of Doses.............................................................................32
7.3.
Blinding .......................................................................................................................32
7.4.
Dose Modification........................................................................................................33
7.4.1.
Management of Intravenous Infusion ...................................................................33
7.4.1.1.
Premedication for Infusions............................................................................33
7.4.1.2.
Management of Infusion Reactions.................................................................33
7.5.
Preparation/Handling/Storage/Accountability...............................................................34
7.6.
Treatment Compliance .................................................................................................34
7.7.
Concomitant Therapy...................................................................................................34
7.8.
Treatment after the End of the Study............................................................................35
8.
Discontinuation Criteria ....................................................................................................36
8.1.
Discontinuation from Study Treatment.........................................................................36
8.1.1.
Discontinuation of Inadvertently Enrolled Subjects..............................................36
8.2.
Discontinuation from the Study....................................................................................36
8.3.
Subjects Lost to Follow-up...........................................................................................37
9.
Study Assessments and Procedures ...................................................................................38
9.1.
Efficacy Assessments...................................................................................................38
9.2.
Adverse Events ............................................................................................................38
9.2.1.
Serious Adverse Events........................................................................................39
9.2.1.1.
Suspected Unexpected Serious Adverse Reactions..........................................39
9.2.2.
Complaint Handling.............................................................................................39
9.3.
Treatment of Overdose.................................................................................................40
9.4.
Safety...........................................................................................................................40
9.4.1.
Laboratory Tests ..................................................................................................40
9.4.2.
Vital Signs ...........................................................................................................40
9.4.3.
Electrocardiograms ..............................................................................................40
9.4.4.
Body Weight........................................................................................................41
9.4.5.
Safety Monitoring ................................................................................................41
9.4.5.1.
Hepatic Safety................................................................................................41
9.4.6.
Hypersensitivity Reactions...................................................................................42
9.4.6.1.
Injection-Site Reactions..................................................................................42
9.4.6.1.1.
Pain Measurements Using the Visual Analog Scale...................................42
9.4.7.
Glucose Monitoring (Part C)................................................................................42
9.4.7.1.
Hyperglycemia and Hypoglycemia Reporting.................................................43
9.4.8.
Nausea and Vomiting...........................................................................................45
9.4.9.
Elevated Lipase or Amylase.................................................................................45

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 4
LY3298176
9.4.10.
Immunogenicity Assessments ..............................................................................45
9.5.
Pharmacokinetics .........................................................................................................46
9.5.1.
Bioanalysis...........................................................................................................46
9.6.
Pharmacodynamics ......................................................................................................46
9.7.
Genetics .......................................................................................................................47
9.8.
Biomarkers...................................................................................................................47
9.9.
Health Economics ........................................................................................................47
10.
Statistical Considerations and Data Analysis.....................................................................48
10.1. Sample Size Determination ..........................................................................................48
10.2. Populations for Analyses..............................................................................................48
10.2.1.
Study Participant Disposition ...............................................................................48
10.2.2.
Study Participant Characteristics ..........................................................................48
10.3. Statistical Analyses ......................................................................................................48
10.3.1.
Safety Analyses....................................................................................................49
10.3.1.1.
Clinical Evaluation of Safety..........................................................................49
10.3.1.2.
Statistical Evaluation of Safety.......................................................................49
10.3.1.3.
Injection Site Reaction....................................................................................49
10.3.2.
Pharmacokinetic Analyses....................................................................................49
10.3.2.1.
Pharmacokinetic Parameter Estimation...........................................................49
10.3.2.2.
Pharmacokinetic Statistical Inference .............................................................49
10.3.2.2.1.
Part A .......................................................................................................49
10.3.2.2.2.
Part B .......................................................................................................50
10.3.2.2.3.
Part C .......................................................................................................50
10.3.3.
Evaluation of Immunogenicity .............................................................................50
10.3.4.
Data Review during the Study..............................................................................50
11.
References ........................................................................................................................51

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 5
LY3298176
List of Tables
Table
Page
Table GPGE.4.1
Objectives and Endpoints .......................................................................22
Table GPGE.7.1
Treatments Administered........................................................................32

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 6
LY3298176
List of Appendices
Appendix
Page
Appendix 1.
Abbreviations and Definitions ................................................................53
Appendix 2.
Clinical Laboratory Tests........................................................................58
Appendix 3.
Study Governance, Regulatory, and Ethical Considerations....................59
Appendix 4.
Hepatic Monitoring Tests for Treatment-Emergent Abnormality ............62
Appendix 5.
Blood Sampling Summary......................................................................63
Appendix 6.
Clinically Significant Adverse Effects ....................................................65
Appendix 7.
Pancreatic Monitoring ............................................................................67
Appendix 8.
Contraceptive Methods...........................................................................70

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 7
LY3298176
1. Protocol Synopsis
Title of Study:
Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects 
Rationale: 
A solution formulation of LY3298176 will be evaluated in upcoming Phase 3 studies. This solution formulation has
a different composition from the lyophilized formulation for injection that was used in the Phase 1 study, and is 
being used in the ongoing Phase 2 studies. 
Part A: Investigate the relative bioavailability of the solution formulation (test), compared to the lyophilized 
formulation (reference). 
Part B: The pharmacokinetics (PK) of LY3298176 following administration via intravenous (IV) route will be 
investigated. 
Part C: The safety, tolerability, and PK of LY3298176, following administration of up to a 10-mg dose via a 
titration regimen using a solution formulation.
Objective(s)/Endpoints:  
Objectives
Endpoints
Part A:

Primary: To evaluate the PK of a single SC 
dose of LY3298176, administered as solution 
formulation (test) versus lyophilized 
formulation (reference) in healthy subjects

Secondary: To investigate the safety and 
tolerability of LY3298176, administered to 
healthy subjects 

PK parameters, including AUC and Cmax, 

AEs and injection site reactions
Part B: 

Primary: To evaluate the PK of a single IV
dose of LY3298176 in healthy subjects

Secondary: To investigate the safety and 
tolerability of LY3298176, administered to 
healthy subjects via IV formulation

PK parameters, including AUC 

AEs
Part C:

Primary: To evaluate the safety and 
tolerability of LY3298176, following multiple  
SC weekly doses of a solution formulation
administered in healthy subjects.

Secondary: To evaluate the PK of 
LY3298176, administered as a solution 
formulation 

AEs and injection site reactions

PK parameters including AUC and Cmax
Abbreviations:  AEs = adverse events; AUC = area under the drug plasma concentration versus time curve; 
Cmax = maximum observed concentration; IV = intravenous(ly); PK = pharmacokinetic(s); SC = subcutaneous(ly).

I8F-MC-GPGE(a)Clinical Pharmacology Protocol
Page 8
LY3298176
Summary of Study Design:  
Study I8F-MC-GPGE is a single-center, Phase 1,Part A is a 2-period crossover study in healthy subjects to evaluate 
the relative bioavailability of a 5-mg solution formulation (test) administered subcutaneously (SC), compared to 
reconstituted lyophilized formulation (reference).  Part B is a single-arm study in healthy subjects to evaluate the PK 
of 0.5-mg solution formulationofLY3298176 following IV administration.  Part C will be conducted in healthy 
subjectsevaluating safety, tolerability, and PK of doses up to 10mg, administered via titration, using a solution 
formulation.
Treatment Arms and Planned Durationfor an Individual:  
Part A: Subjectswill be screened over a28 dayperiod and will be randomized to 1 of 2treatment sequences,
according to the randomization table provided to the site.  Each subjectwill receive a single SCinjection of 
LY3298176 test formulation and a reference formulation in a 2 arm cross over design. Subjects will be admitted to 
the clinical research unit (CRU) on Day -1 and discharged on Day 8 of eachperiodand will return to the CRU for 
Day 15, Day 21, and Day 35-37procedures each period.  Each dose will be separated by a minimum of 35 days.  A
follow-up (or early discontinuatio
n)visit should occur 35-37days after the last dose of the study drug.
Part B: Subjects will be screened over a28-dayperiod. Subjects will be admitted to the CRU on Day -1. On 
Day1, following an overnight fast of at least 8 hours, subjects will receive a single IV dose of LY3298176solution 
formulation, administered over 10 minutes. At a minimum, subjects will remain inthe CRU for 8 days. Subjects 
may be required to remain inthe CRUforlonger than Day 8,at the investigator’s discretion. Subjects will return to 
the CRU onDay 15, Day 35-37and at greater than or equal to 70 dayspost-dose.
Part C: Subjectswill be screened over a28-day period.  Subjects willbe randomized toreceive LY3298176 or 
placebo in doses of 5mg (Day1), 5mg (Day 8), 7.5mg (Day 15), and 10mg(Day 22).Treatment will be
administered via solution formulationat each of the doses.Subjectswill be required to attend follow-upvisits35 
days after the last doseand at least 70 days after the last dose.
Number of Subjects:
Up to 46adult subjects will be enrolled to ensure that 34complete the study:
Up to 20 healthy subjects will be enrolled in order thatatleast 16 complete Part A
Up to 10 healthy subjects will be enrolled in order thatatleast 6complete Part B
Up to 16healthy subjectswill be enrolled inorder thatatleast 12complete Part C
Statistical Analysis:
Safety:
Continuous safety variables will be summarized using descriptive statistics.  Categorical safety variables will be 
summarized using countand percentage.  Vital signs data will be analyzed and summarized for each Part.
Pharmacokinetic:
Part A:   To evaluatethe PK for the 2formulations, area under the drug plasma concentration versus time curve 
from time zero to infinity (AUC[0-∞]), and maximum drug  plasma concentration (Cmax)will be log transformed and 
analyzedusing a linear mixed-effects model with treatment, period, and sequence as fixed effects,and subject as a 
random effect.  The treatment ratio and the corresponding 90% confidence intervals [CIs]of the ratios will be 
reported.
Part B:  Pharmacokineticparameters will be summarized descriptively.
Part C:  Pharmacokineticparameters will be summarized descriptively.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 9
LY3298176
2. Schedule of Activities

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 10
LY3298176
2.1.
Study Schedule Protocol I8F-MC-GPGE, Part A
Procedure (Part A) 
Screening
Periods 1 and 2
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
21
35 -
37 post 
dose 
period 1
35 -
37 post 
dose 
period 2
≥35 day washout 
between doses 1 
and 2. 
Informed Consent
X
Subject Admission to 
CRU
X
Subject Discharge from 
CRU
X
Subjects may stay 
longer according to 
investigator 
discretion
Outpatient Visit
X
X
X
X
X
X
Investigational Product 
Administration
X
There is a minimum 
of 35 days washout 
period between 
doses for Period 1 
and Period 2.   
Study drug will be 
administered SC 
after an overnight 
fast of at least 8 
hours.
Medical History
X
Height
X
Weight
X
X
X
X
X
Vital Signs 
(BP/PR/T) (supine) 
X
X
P
24
48
X
X
X
X
X
X
Time points may be 
added for each 
study period, if 
warranted and 
agreed upon 
between Lilly and 
the  investigator.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 11
LY3298176
Procedure (Part A) 
Screening
Periods 1 and 2
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
21
35 -
37 post 
dose 
period 1
35 -
37 post 
dose 
period 2
≥35 day washout 
between doses 1 
and 2. 
Clinical Laboratory Tests
X
X
X
X
X
X
See Appendix 2, 
Clinical Laboratory 
Tests, for details.  
Adverse Event
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Injection Site Reaction 
Assessment
P, 0, 
6h, 12h
24h
48h
0-hour assessment 
should be 
performed within 
5 minutes after 
subcutaneous 
injection.  
Additional 
assessments may be 
performed if 
deemed necessary 
by the investigator. 
Visual analog scale 
(VAS) score will be 
recorded
PK Samples 
P, 8h, 
12h,
24h
48h
72h
96h
120h
144h
168h
336h
480h
X
X
X
Sampling times are 
relative to the start 
of dose 
administration (0 
hr).  Predose sample 
must be collected 
before dose 
administration. If a 
subject withdraws 
from the study prior 
to completion of 
scheduled PK 
sampling for a 
given period, every 
effort will be taken 
to draw an 
unscheduled blood 
sample for PK 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 12
LY3298176
Procedure (Part A) 
Screening
Periods 1 and 2
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
21
35 -
37 post 
dose 
period 1
35 -
37 post 
dose 
period 2
≥35 day washout 
between doses 1 
and 2. 
assessment.  This 
will not be required 
if a sample has 
already been taken 
within the previous 
24 hours. For ET, 
a PK sample can be 
taken at any time 
during the visit 
timed close to the 
immunogenicity 
sample.
Pregnancy Test 
X
X
X
X
X
All females only.  
Serum pregnancy 
test will be 
performed at 
screening.  Urine 
pregnancy test will 
be performed at 
Day -1 for each 
period and at 
ET/Follow-up.
Physical Examination
X
X
X
X
X
X
After screening, 
medical assessment 
only performed to 
include medical 
review and targeted 
examination, as 
appropriate.
12-lead ECG
X
X
X
X
X
X
Single 12-lead ECG 
will be collected.  
ECGs must be 
recorded before 
collecting any blood 
samples.  Subjects 
must be supine for 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 13
LY3298176
Procedure (Part A) 
Screening
Periods 1 and 2
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
21
35 -
37 post 
dose 
period 1
35 -
37 post 
dose 
period 2
≥35 day washout 
between doses 1 
and 2. 
at least 5 minutes 
before ECG 
collection and 
remain supine but 
awake during ECG 
collection.
Genetic Sample
P
Single sample for 
pharmacogenetic 
analysis taken prior 
to dosing on Day 1 
in Period 1 only.
Immunogenicity Samples
P
X
X
X
X
All samples for 
immunogenicity 
should be taken 
predose for period 1 
and 2.  Day ≥35 
post dose 2 and at 
follow-up (Day 
≥70).  
Time-matched PK 
sample should be 
collected at each 
time point.
Abbreviations:  BP = blood pressure; CRU = clinical research unit; ECG = electrocardiogram; ET = early termination; h = hours; P = Predose; 
PK = pharmacokinetics; PR = pulse rate; T = Temperature; VAS = visual analog scale.
Note:  If multiple procedures take place at the same time point, the following order of the procedures should be used:  ECGs, vital signs, and venipuncture.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 14
LY3298176
2.2.
Study Schedule Protocol I8F-MC-GPGE, Part B
Procedure
(Part B)
Screening
Treatment
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
35 - 37
≥70 days
Informed 
Consent
X
Subject 
Admission to 
CRU
X
Subject 
Discharge from 
CRU
X
Subjects may stay 
longer according to 
investigator 
discretion
Outpatient Visit
X
X
X
X
X
Investigational 
Product 
Administration
X
Study drug will be 
administered after an 
overnight fast of at 
least 8 hours. Study 
drug will be 
administered over 10 
min IV infusion
Medical History
X
Height
X
Weight
X
X
X
X
Vital Signs 
(BP/PR/T) 
(supine) (hours)
X
X
P
24h
48h
X
X
X
Time points may be 
added for each study 
period, if warranted 
and agreed upon 
between Lilly and the 
investigator.
Clinical 
Laboratory 
Tests
X
X
X
X
X
Requires an 8 hour 
fast. See Appendix 2, 
for details.  
Adverse Event
X
X
X
X
X
X
X
X
X
X
X
X
X

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 15
LY3298176
Procedure
(Part B)
Screening
Treatment
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
35 - 37
≥70 days
PK Samples 
P, 5 
min, 
10 
min, 
30 
min 
1h, 
2h, 
4h,  
8h, 
12h,
24 h, 
36 h
48 h
72h
96h
120h
144h
168h
336
h
X
X
X
All sampling times 
are from start of 
infusion. (0 hr). 
Predose sample must 
be collected before 
dose administration. 
If a subject withdraws 
from the study prior 
to completion of 
scheduled PK 
sampling, every effort 
will be taken to draw 
an unscheduled blood 
sample for PK 
assessment.   This 
will not be required if 
a sample has already 
been taken within the 
previous 24 hours.  
For ET, a PK sample 
can be taken at any 
time during the visit 
timed close to the 
immunogenicity 
sample.
Pregnancy Test 
X
X
X
X
All females only.  
Serum pregnancy test 
will be performed at 
screening.  Urine 
pregnancy test will be 
performed at Day -1  
and at ET/Follow-up.
Physical Exam
X
X
X
X
X
After screening, 
medical assessment 
only performed to 
include medical 
review and targeted 
examination, as 
appropriate.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 16
LY3298176
Procedure
(Part B)
Screening
Treatment
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
35 - 37
≥70 days
12-lead ECG
X
X
X
X
X
Single 12-lead ECG 
will be collected.  
ECGs must be 
recorded before 
collecting any blood 
samples.  Subjects 
must be supine for at 
least 5 minutes before 
ECG collection and 
remain supine but 
awake during ECG 
collection.
Genetic Sample
P
Single sample for 
pharmacogenetic 
analysis taken prior to 
dosing on Day 1.
Immunogenicity 
Samples
P
X
X
X
X
All samples for 
immunogenicity 
should be taken 
predose and follow 
up.  Time-matched 
PK sample should be 
collected at each time 
point.
Abbreviations:  BP = blood pressure; CRU = clinical research unit; ECG = electrocardiogram; ET = early termination; hr = hour(s); IV = intravenous(ly); 
min = minute(s); P = Predose; PK = pharmacokinetic(s); PR = pulse rate; T= Temperature
Note:  If multiple procedures take place at the same time point, the following order of the procedures should be used:  ECG, vital signs, and venipuncture.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 17
LY3298176
2.3.
Study Schedule Protocol I8F-MC-GPGE Part C
Procedure (Part 
C)
Screen
Prestudy
Treatment
ET/Follow-
up
Days
-28 to -2
Before −2
−1
1
2
3
4
8a
9
10
15 a
16
17
18
22 a
23
24
25
57
≥92
Informed consent
X
Admission to 
CRUc
X
X
X
X
Discharge from 
CRU
X
X
X
X
Outpatient visits 
to CRU
X
X
X
X
X
Distribution of 
glucose meters, 
test strips, diary, 
and GM training
X
Distribution of 
additional test 
strips, and diary. 
X
X
X
Administer study 
drugd
X
X
X
X
Medical history
X

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 18
LY3298176
Procedure (Part 
C)
Screen
Prestudy
Treatment
ET/Follow-
up
Days
-28 to -2
Before −2
−1
1
2
3
4
8a
9
10
15 a
16
17
18
22 a
23
24
25
57
≥92
Height and 
weighte
X
X
P
P
P
P
X
Physical 
examination
X
Medical 
assessmentf
X 
P
P
P
P
X
Vital signs 
(BP/PR/T)g
(hours)
X
X
P
X
X
P
X
X
P
X
X
P
X
X
X
ECGh
X
P
P
X
PK sampling
(hours)
P,
8h
2
4
h
48
h
72h
P
P, 
8h
24
h
48
h
72
h
P, 
8h
24
h
48
h
72
h
X
X
Clinical laboratory 
testsi
X
P
P
X
AEs/concomitant 
medications
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Injection site 
reactionsb
P, 
0, 
6h , 
12h
2
4
h
P, 
0, 
6h
, 
12
h
24
P, 
0, 6,
12
24
P, 
0, 6, 
12
24

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 19
LY3298176
Procedure (Part 
C)
Screen
Prestudy
Treatment
ET/Follow-
up
Days
-28 to -2
Before −2
−1
1
2
3
4
8a
9
10
15 a
16
17
18
22 a
23
24
25
57
≥92
Pharmacogenomic 
sample
X
Immunogenicity
P
P
X
X
Abbreviations:  AEs = adverse events; BP = blood pressure; CRU = clinical research unit; ECG = electrocardiogram; ET = early termination; GM = glucose 
monitoring; h = hours; P = Predose; PK = pharmacokinetic(s); PR = pulse rate; T= temperature.
a
Dosing day – subjects will be admitted to CRU the day prior to dosing.
b
Visual analog scale (VAS) score will be recorded
c
For each CRU admission, subjects must remain at the CRU at least 72 hours postdose or per medical judgment.
d
Study drug will be administered after an overnight fast of at least 8 hours.
e
Height measured at screening only.  Weight will be measured twice in a consistent way, each predose.  Scale needs to be calibrated (refer to Section 9.4.4).
f
Medical assessment will include a physical examination.
g
Vital signs(BP/PR/T) measurements:  for each dose day: predose, 24 hr, 48 hr, and on or after Day 92 (follow-up/ET).
h
Single local safety ECGs will be measured at screening, predose Day 1, predose Day 22, predose Day 50 and follow-up/ET to take place on or after Day 92
(follow-up).  Electrocardiograms must be recorded before collecting any blood for safety or PK samples and close to the time of the blood draw.  Subjects 
must be supine for approximately 5 to 10 minutes before ECG collection and remain supine, but awake, during ECG collection.
i
Clinical safety laboratory measures include chemistry, hematology, and urinalysis panels.  Blood samples will be taken predose on all dosing days.  Subjects
will be required to fast for at least 8 hours before each blood sample is drawn.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 20
LY3298176
3. Introduction
3.1.
Study Rationale
Study I8F-MC-GPGE is a single-center, Phase 1, 3-part study to be conducted in healthy 
subjects.
A new solution formulation of LY3298176 will be evaluated in upcoming Phase 3 studies.
This formulation has a different composition from the lyophilized formulation for injection that 
was used in the Phase 1 study and is also being used in the ongoing Phase 2 studies.
In Part A of the study, the study will evaluate the relative bioavailability of a 5-mg dose of 
LY3298176, administered subcutaneously (SC) as solution formulation (test), compared to a 
5-mg dose, administered after reconstituting a lyophilized formulation (reference). These data 
will support Phase 3 clinical development.
LY3298176 has not been administered to subjects via the intravenous (IV) route to date;
therefore, in Part B of the study, we will evaluate the pharmacokinetics (PK) of LY3298176 
following IV administration.  This information will enable us to calculate the absolute 
bioavailability of LY3298176 following SC administration (using prior SC PK data from 
Phase 1), which was the route utilized in the Phase 1 study, and is the intended route of 
administration for this drug as a therapeutic. 
Part C will evaluate the safety, tolerability, and PK of LY3298176 doses up to 10 mg.
Doses will be administered via a weekly titration regimen in healthy subjects. These data will 
support Phase 3 clinical development.
3.2.
Background
LY3298176 is being investigated for its potential use in the treatment of type 2 diabetes mellitus 
(T2DM).  LY3298176 is a long-acting, dual incretin receptor co-agonist that binds to both the 
glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 
(GLP-1) receptor.  As a co-agonist, LY3298176 combines the signaling of each receptor for 
potentially improved glycemic control.  LY3298176 consists of a peptide component, which is 
based on the GIP sequence, conjugated to a C20 fatty acid moiety that prolongs the duration of 
action, allowing for once weekly (QW) SC administration.  Because it is a co-agonist, 
LY3298176 has the potential of reaching high efficacy in target tissues (such as the insulin-
producing pancreatic -cells that express both GIP and GLP-1 receptors) before reaching its 
therapeutic limitation.  Furthermore, LY3298176 may attain additional efficacy by recruiting 
metabolically active tissues (eg, adipose tissue) not targeted by classical GLP-1 receptor 
agonists.  This may result in increased energy utilization and greater weight loss in T2DM 
patients than that observed with GLP-1 receptor agonists (GLP-1 RAs) alone (Baggio and 
Drucker 2007).
The safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of LY3298176 were 
evaluated in the Phase 1 clinical pharmacology trial, I8F-MC-GPGA (GPGA).  Preliminary data 
are available. In Study GPGA, LY3298176 was administered as an SC injection in a single dose 
(0.25 to 8 mg) and in 4 QW doses (0.5 to 10 mg with doses >5 mg reached through dose 

I8F-MC-GPGE(a)Clinical Pharmacology Protocol
Page 21
LY3298176
titration) to healthy subjects.  LY3298176 was also administered SC to patients with T2DM in 
4QW doses (0.5 to 15mg with doses >5 mg reached through dose titration).  In both healthy 
volunteers and patients with T2DM, there was a suppression of serum glucose and a reduction of 
postprandial glucose that was generally dose-dependent.  There was also a decrease in body 
weight that was generally dose-dependent.  Nausea, vomiting, and diarrhea were frequently 
reported adverse events (AEs).  Higher doses were better tolerated using a dose titration scheme 
of administration.  Increases in heart rate were observed following administration of LY3298176,
compared with placebo.  There were no clinically significant changes in systolic or diastolic 
blood pressure or QT/corrected QT (QTc)interval prolongation observed in either healthy 
volunteers or patients with T2DM.  No subject appeared to develop neutralizing antibodies to 
LY3298176.
In summary, LY3298176 has exhibited the expected GLP-1 pharmacological effects on glucose 
suppression.  The body weight loss may be due to pharmacology of higher GLP-1 doses or due 
to contribution of the GIP part of the molecule.  The reported gastrointestinal-(GI-)related AEs 
are consistent with GLP-1 pharmacology and those observed previously following administration 
of GLP-1 RAs (Nauck et al. 2009; Dungan et al. 2014; Giorgino et al. 2015; Jendle et al. 2016; 
Nauck et al. 2016).  The effects observed on heart rate have also been observed with other GLP-1
RAs and have not been associated withadverse cardiovascular (CV) outcomes (Herbst et al. 
2017).
3.3. Benefit/Risk Assessment
The nonclinical dataand preliminary clinical data (See Section 3.2) from Study GPGA support 
furtherclinical development for LY3298176. 
Predicted exposure multiples were derived from repeat-dose toxicology studies,using the highest
proposed clinical dose of 15 mg/week. 
 
 
The effects in rats and monkeys included decreases 
in body weight and/or body weight loss, decreases in food consumption, and dehydration. All of 
the changes were consistent with, or secondary to, GLP-1 pharmacology,and wereeasily 
monitoredin clinical studies. Furthermore, there was no evidence of target organ toxicity in either 
species. For more information, reference the Investigator’s Brochure(IB).
No clinically significant safety or tolerabilityconcerns were identified up to the highest single 
dose level of 8 mgor following 4 QW doses titrated up to 10 mg in Study GPGA. Based on this 
information,doses to be administeredin Study GPGE will be tolerable to healthy subjects.
Anyidentified potential risks are similar with the risks associated with currently available long-
acting GLP-1 receptor agonists (See Section 3.2)
CCI
, are considered to be manageable,and areable 
to be monitored.
More information about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably anticipated AEs ofLY3298176is found in the compound IB.  

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 22
LY3298176
4. Objectives and Endpoints
Table GPGE.4.1 shows the objectives and endpoints of the study.
Table GPGE.4.1
Objectives and Endpoints
Objectives
Endpoints
Part A:

Primary: To evaluate the PK of a single SC 
dose of LY3298176, administered as solution 
formulation (test) versus lyophilized 
formulation (reference) in healthy subjects.

Secondary: To investigate the safety and 
tolerability of LY3298176, administered to 
healthy subjects.

PK parameters, including AUC and Cmax, 

AEs and injection site reactions
Part B: 

Primary: To evaluate the PK of a single IV
dose of LY3298176 in healthy subjects.

Secondary: To investigate the safety and 
tolerability of LY3298176, administered to 
healthy subjects via IV formulation.

PK parameters, including AUC 

AEs
Part C:

Primary: To evaluate the safety and 
tolerability of LY3298176, following multiple 
SC weekly doses of a solution formulation
administered in healthy subjects.

Secondary:  To evaluate the PK of 
LY3298176, administered as a solution 
formulation.

AEs and injection site reactions

PK parameters including AUC and Cmax
Abbreviations:  AEs = adverse events; AUC = area under the drug plasma concentration versus time curve; 
Cmax= maximum observed concentration; IV = intravenous(ly); PK = pharmacokinetic(s); SC = subcutaneous(ly).

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 23
LY3298176
5. Study Design
5.1.
Overall Design
Study I8F-MC-GPGE (GPGE) is a single-center, Phase 1 study conducted in healthy subjects in 
3 parts: Part A is a 2-period, 2-treatment, crossover design evaluating the relative bioavailability 
of 2 formulations of LY3298176; Part B, a single-arm design evaluating LY3298176 PK with IV 
administration; and Part C is a placebo-controlled, single-arm design evaluating the safety, 
tolerability, and PK of LY3298176 titrated, once-weekly for 4 weeks.
Part A: Part A is a randomized, 2-period, crossover study in healthy subjects to evaluate the 
relative bioavailability of 5 mg LY3298176, administered as a solution formulation (test),
compared to a 5-mg dose administered SC as lyophilized formulation (reference). Treatment 
sequences and randomization are described in Section 7.2.
Each subject will provide informed consent for study participation, and will undergo a screening 
examination within 28 days prior to enrollment.
In each treatment period, subjects will be admitted to the clinical research unit (CRU) on Day -1.  
On the morning of Day 1, following an overnight fast of at least 8 hours, subjects will receive a 
single SC dose of LY3298176, administered according to their assigned treatment sequences.  
Blood samples will be collected predose and up to 480 hours postdose to measure LY3298176
concentrations. At a minimum, subjects will remain in the CRU for 8 days.  The investigator (or 
qualified designee) will review all available inpatient safety data before discharging subjects 
from the CRU on the morning of Day 8, provided that the subjects are deemed medically fit. 
Subjects may be required to remain in the CRU longer than Day 8, at the investigator’s 
discretion. The subjects will return to the CRU for follow-up visits on Days 21 and 35-37.
There will be a washout period of at least 35 days between doses in Periods 1 and 2. Based on 
the PK properties of LY3298176 (terminal half-life: approximately 5 days), a washout period of 
at least 35 days between doses in Periods 1 and 2 is considered adequate. Period 2 will repeat 
the same schedule as Period 1 with the Day 35 visit being the final study visit, which will include 
an antidrug antibody (ADA) sample at least 10 weeks after the first dose.  
Part B:  Part B is a single, 0.5-mg IV dose of LY3298176 solution formulation (or lyophilized 
formulation in absence of solution formulation) administered to healthy subjects.
Each subject will provide informed consent for study participation, and will undergo a screening 
examination within 28 days prior to enrollment.
Subjects will be admitted to the CRU on Day -1. On the morning of Day 1, following an 
overnight fast of at least 8 hours, 2 subjects will receive a single IV dose of 0.5 mg LY3298176, 
administered over 10 minutes. This dose is expected to be safe while also providing plasma 
concentrations that can be adequately measured over the course of the sampling time period to 
enable adequate characterization of the PK profile.

If the dose of 0.5 mg is found to be safe and well-tolerated, then a PK interim analysis 
will be performed.  Based on the results of the interim analysis, if it is noted that 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 24
LY3298176
LY3298176 concentrations can be adequately quantified, then 4 more subjects will be 
dosed.

If the dose of 0.5 mg is found to be safe and well-tolerated, then a PK interim analysis 
will be performed. Based on the results of the interim analysis, if it is noted that 
LY3298176 concentrations cannot be adequately quantified, then a dose adjustment
(however less than 1 mg) may be considered for an additional 6 subjects.

If the dose is not tolerated due to extensive GI events, a lower dose of 0.25 mg (infused 
over 10 minutes) may be administered to an additional 6 subjects. 
Plasma samples will be collected multiple times, including predose and up to 336 hours 
postdose, to measure LY3298176 concentrations.  
At a minimum, subjects will remain in the CRU for 8 days.  The investigator (or qualified 
designee) will review all available inpatient safety data before discharging subjects from the 
CRU on the morning of Day 8, provided that the subjects are deemed medically fit.  Subjects 
may be required to remain in the CRU longer than Day 8, at the investigator’s discretion.
Each subject will be required to return to the CRU for a follow-up visit at least 35 days after the 
LY3298176 dose.  In addition, subjects will need to attend a study visit on Day ≥70 for an ADA
follow-up sample.
Part C:  Part C is a randomized, titration study where healthy subjects will be assigned 
LY3298176 or placebo at a ratio of 3 LY subjects to 1 placebo subjects. The investigator and 
subject will be blinded to the treatment. .
Subjects will receive a treatment regimen of either LY3298176 or placebo to be given as a SC 
dose on Days 1, 8, 15, and 22, after an overnight fast (at least 8 hours). Subjects randomized to
LY3298176 will receive a 5-mg dose on Day 1 and Day 8, a 7.5-mg dose on Day 15, and a 10-
mg dose on Day 22, administered via solution formulation (treatment specifics can be found in 
Section 7.1).
Each subject will be required to return to the CRU for outpatient visits and for a follow-up visit  
on Day ≥92.
For all parts of this study pharmacokinetic sampling and safety assessments, including AE
recording, medical assessments, clinical laboratory tests, vital signs measurement, and 
electrocardiograms (ECGs), will be performed according to the Schedule of Activities 
(Section 2). 
Subjects will be admitted the day before dosing.  The investigator (or qualified designee) will 
review all available inpatient safety data before discharging subjects from the CRU on Day 3 
after the final study procedures, provided that the subjects are deemed medically fit. More 
information is outlined in the Schedule of Activities (Section 2.3). 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 25
LY3298176
5.2.
Number of Participants
Part A: Approximately 20 healthy subjects will be enrolled so that at least 16 complete 
this part.
Part B:  Approximately 10 healthy subjects will be enrolled so that at least 6 complete 
this part.
Part C:  Approximately 16 healthy subjects will be enrolled so that at least 12 complete 
this part.
For purposes of this study, a subject completes the study when all scheduled procedures shown 
in the Schedule of Activities (Section 2) have been finished.
5.3.
End of Study Definition
The end of the study is the date of the last visit or last scheduled procedure shown in the 
Schedule of Activities (Section 2) for the last subject entered into any part of the study.
5.4.
Scientific Rationale for Study Design
In this study, a population of healthy subjects is selected based on the likelihood of less 
physiologic variability in the absence of disease states that may affect multiple organ systems 
and absence of other confounding factors, such as concomitant medications.  Part A is a
randomized, open-label, single-dose, crossover-design study. The use of a crossover design 
allows each subject to serve as his/her own control, thereby, reducing variability.
Part B, will investigate the PK of LY3298176 following administration via a single IV dose.
An interim analysis will be performed after dosing the first 2 subjects to review safety and 
tolerability, and to check if there is a need for dose adjustment prior to dosing the rest of the 
subjects. 
Part C will evaluate the safety, tolerability, and PK of doses up to 10 mg attained via a 4-week 
titration regimen in healthy subjects, when administered via a solution formulation planned for 
use in the Phase 3 study, compared to placebo. The titration algorithms have been chosen based 
on safety and tolerability data from the Phase 1 study, GPGA.
5.5.
Dose Justification
5.5.1. Part A
A 5-mg LY3298176 dose is selected for Part A of the study to enable comparison of the solution 
formulation (test) versus the lyophilized formulation (reference). A 5-mg dose has been 
previously studied in healthy subjects and T2DM patients (Study GPGA), and was found to be 
safe and tolerable. 
5.5.2. Part B
A starting dose of 0.5 mg LY3298176 (administered IV over 10 minutes) is chosen because this 
dose is expected to lead to a measureable PK profile with a modest observed peak drug 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 26
LY3298176
concentration (Cmax), while still leading to peak and overall exposures notably lower than those 
observed following administration of a 5-mg SC dose (which has been studied in the Phase 1 
study, GPGA). This dose will be administered such that up to 2 subjects will receive an initial 
dose of 0.5 mg, administered over 10 minutes. If this dose is found to be safe in the first 
2 subjects, an interim analysis will be performed to evaluate the PK data in these subjects.
After the interim analysis, it will be decided whether to administer the same 0.5-mg dose to all 
the remaining subjects in this arm or to evaluate a different dose. If it is noted that LY3298176
concentrations cannot be adequately quantified, then a dose adjustment may be considered for an 
additional 6 subjects.
If the 0.5-mg dose is not tolerated, a lower dose of 0.25 mg (infused over 10 minutes) may be 
administered to an additional 6 subjects. 
5.5.3. Part C
The planned dose-titration scheme to be tested in healthy subjects in this part of the study will be 
comprised of a QW titration dosing regimen of 5 mg, 5 mg, 7.5 mg, and 10 mg, compared to 
placebo. The titration algorithms have been chosen based on safety and tolerability data from the 
Phase 1 study, GPGA.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 27
LY3298176
6. Study Population
Eligibility of subjects for the study will be based on the results of screening medical history, 
physical examination, vital signs, clinical laboratory tests, and ECGs.  The nature of any 
conditions present at the time of the physical examination and any preexisting conditions will be 
documented. 
Screening may occur up to 28 days prior to enrollment.  Subjects who are not enrolled within
28 days of screening may be subjected to an additional medical assessment and/or clinical 
measurements to confirm their eligibility.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.
6.1.
Inclusion Criteria
Subjects are eligible for inclusion in the study only if they meet all of the following criteria at 
screening:
[1]
are overtly healthy males or females, as determined by medical history and 
physical examination.
[1a] Male subjects:
agree to use an effective method of contraception for the duration of the 
study and for 3 months following the last dose of investigational product
(see Appendix 8 for acceptable methods of contraception).
[1b] Female subjects:
women not of childbearing potential due to surgical sterilization 
(hysterectomy or bilateral oophorectomy or tubal ligation) or 
menopause.  Women with an intact uterus are deemed postmenopausal if 
they are ≥45 years old,
AND
have not taken hormones or oral contraceptives within the last year and 
had cessation of menses for at least 1 year.
OR
have had at least 6 months of amenorrhea with follicle-stimulating hormone 
levels consistent with a postmenopausal state.
[2]
are males or females between 18 and 70 years old.
[3]
have a screening body mass index of >18.5 and ≤32.0 kg/m2.
[4]
have clinical laboratory test results within normal reference range for the 
population or investigative site, or results with acceptable deviations that are 
judged to be not clinically significant by the investigator.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 28
LY3298176
[5]
have blood pressure of <160/90 mmHg and pulse rate of 50 to 90 bpm
(supine) at screening, or with minor deviations judged to be acceptable by the 
investigator.
[6]
are reliable and willing to make themselves available for the duration of the 
study, and are willing to follow study procedures.
[7]
are able and willing to give signed informed consent.
[8]
have venous access sufficient to allow for blood sampling as per the protocol.
6.2.
Exclusion Criteria
Subjects will be excluded from study enrollment if they meet any of the following criteria at 
screening and/or enrollment:
[9]
are investigative site personnel directly affiliated with this study or their 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian, child, or sibling.
[10] are Lilly employees.
[11] are currently enrolled in a clinical trial involving an investigational product or 
any other type of medical research judged not to be scientifically or medically 
compatible with this study.  
[12] have received treatment with a drug that has not received regulatory approval 
for any indication within 30 days of screening.
[13] have previously completed or withdrawn from this study or any other study 
investigating LY3298176, and have previously received the investigational 
product.
[14] have had any exposure to dulaglutide, other GLP-1 analogs, or other related 
compounds within the prior 3 months, or any history ever of allergies to these 
medications.
[15] have a history of heart block, or a PR interval >200 msec, or any abnormality 
in the 12-lead ECG at screening that, in the opinion of the investigator, 
increases the risks associated with participating in the study.
[16] have a significant history of or current cardiovascular (eg, myocardial 
infarction, congestive heart failure, cerebrovascular accident, venous 
thromboembolism, etc.), respiratory, hepatic, renal, GI, endocrine, 
hematological (including history of thrombocytopenia), or neurological 
disorders capable of significantly altering the absorption, metabolism, or 
elimination of drugs, or of constituting a risk when taking the study 
medication, or interfering with the interpretation of data.
[17] have evidence of significant active neuropsychiatric disease, as determined by 
the investigator.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 29
LY3298176
[18] regularly use known drugs of abuse and/or show positive findings on drug 
screening.
[19] have evidence of human immunodeficiency virus (HIV) infection and/or are 
positive for HIV antibodies.
[20] have evidence of hepatitis C and/or are positive for hepatitis C antibodies.
[21] have evidence of hepatitis B and/or are positive for hepatitis B surface 
antigen.
[22] smoke >10 cigarettes per day, or the equivalent, or are unable or unwilling to 
refrain from nicotine during CRU admission.
[23] have used or plan to use over-the-counter or prescription medication, and/or 
herbal supplements (with the exception of vitamin/mineral supplements, any 
hormone replacement therapy, and/or thyroid replacement therapy) within 
14 days prior to dosing and for the duration of the study, including any 
medications that reduce GI motility, including, but not limited to, 
anticholinergics, antispasmodics, 5-hydroxytryptamine-3 receptor antagonists, 
dopamine antagonists, and opiates.
[24] have had a blood donation of 450 mL or more in the last 3 months, or have 
had any blood donation within the last month prior to screening.
[25] have an average weekly alcohol intake that exceeds 21 units per week (males)
or 14 units per week (females), or are unwilling to stop alcohol consumption 
24 hours before dosing until discharge from CRU.
(1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 
45 mL of distilled spirits)
[26] have a history or presence of pancreatitis (history of chronic pancreatitis or 
idiopathic acute pancreatitis), elevation in serum amylase or lipase (>1.5-fold 
the upper limit of normal [ULN]), GI disorder (eg, relevant esophageal reflux 
or gall bladder disease), or any GI disease which impacts gastric emptying 
(eg, gastric bypass surgery, pyloric stenosis [with the exception of 
appendectomy]) or could be aggravated by GLP-1 analogs or dipeptidyl 
peptidase IV (DPP-IV) inhibitors.  Subjects with dyslipidemia and subjects
who had cholecystolithiasis (with removal of gallstones) and/or 
cholecystectomy (removal of the gall bladder) in the past, with no further 
sequelae, may be included in the study, at the discretion of the investigator.
[27] have a history of atopy or clinically significant multiple or severe drug
allergies, intolerance to topical corticosteroids, or severe posttreatment
hypersensitivity reactions (including, but not limited to, erythema multiforme
major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or
exfoliative dermatitis).
[28] have a personal or family history of medullary thyroid carcinoma or have
multiple endocrine neoplasia syndrome type 2.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 30
LY3298176
[29] have serum aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) >2X the ULN or total bilirubin (TBL) >1.5X ULN.
[30] have a history of malignancy within 5 years prior to screening.
[31] have a serum triglyceride (TG) ≥5 mmol/L (442.5 mg/dL) at screening.
[32] are deemed unsuitable by the investigator for any other reason.
6.2.1. Rationale for Exclusion of Certain Study Candidates
Conflict of interest in study participants is outlined in Criteria [9] and [10].  Excluded medical 
conditions, medication intolerance, and concomitant medication use that may constitute a risk for 
the subject and/or may confound the assessment of study endpoints are described in Criteria [11] 
through [32].
6.3.
Lifestyle and/or Dietary Requirements
Throughout the study, subjects may undergo medical assessments and review of compliance with 
requirements before continuing in the study.  
6.3.1. Meals and Dietary Restrictions
Subjects will be required to fast overnight for at least 8 hours before taking a SC or IV dose of 
LY3298176, and when clinical safety laboratory samples are taken (see Schedule of Activities
[Section 2]). Water may be consumed freely. Standard meals will be administered in the CRU.
6.3.2. Caffeine, Alcohol, and Tobacco
No alcohol will be allowed for at least 24 hours before each CRU admission and each outpatient
visit, and throughout the duration of each CRU visit. Between CRU visits, daily alcohol 
consumption should not exceed 3 units for males and 2 units for females (a unit is defined in 
Exclusion Criterion [25], Section 6.2). No nicotine use will be permitted while in the CRU.
While not resident in the CRU, subjects must consume no more than 10 cigarettes or the 
equivalent per day.
Subjects will be allowed to maintain their regular caffeine consumption throughout the study 
period.
6.3.3. Activity
Subjects should not engage in strenuous physical exercise or activities from 48 hours prior to the 
first dose, and for duration of the study.  When certain study procedures are in progress at the site, 
subjects may be required to remain recumbent or sitting.
6.4.
Screen Failures
Subjects who do not meet the criteria for participation in this study (screen failure) may not be
rescreened.

I8F-MC-GPGE(a)Clinical Pharmacology Protocol
Page 31
LY3298176
7.Treatment
7.1. TreatmentAdministered
This study involves a comparison of drug product LY3298176,for injection thatis being used in 
the Phase1 and ongoing Phase 2 trials to the intended solution formulation of LY3298176 drug 
productfor Phase 3trials over a planned dose range,administered by SC injection. In addition,
the PK of a single IV dose of LY3298176 will be evaluated. Table GPGE.7.1illustrates the 
treatment regimens.
7.1.1. LY3298176 for Injection
LY3298176 for injection, 5 mg, is supplied as lyophilized formulation in a glass vial for SC and 
IV infusion administration.  
 
 
 
  The 
reconstituted product solution in the vial(s) may be held at room temperature and/or refrigerated 
(2°C to 8°C),and should be administered within 4 hours from the time of reconstitution.  
LY3298176 for injection, 5-mg vials,are intended for single-dose administration.
7.1.2. LY3298176 Solution Formulation Injection
CCI
LY3298176 injection is prepared by sterile compounding,and is for SC and IV administration.  
 
 The LY3298176 drug 
product solution vials may be held refrigerated (2°C to 8°C) for not more than 72 hours.The 
drug product solution must be administered within 4 hours after it is removed from refrigerated
(2°C to 8°C) storage.  LY3298176 compounded sterile drug product vials are intended for single-
dose administration.   
All investigational product provided to the investigator will be stored in a secure location, and 
allocated and dispensed by appropriately trained persons.  The allocation and dispensing of the 
investigational products will be fully documented and verified by a second person.  Detailed 
records of the amounts of investigational product received, dispensed,and remaining at the end 
of the study will be maintained. Detailed instructions for the preparation and handling of 
LY3298176 will be provided by the Sponsor in a pharmacy manual.
CCI

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 32
LY3298176
Table GPGE.7.1
Treatments Administered
Treatment Name
LY3298176 
LY3298176 Solution
Placebo to Match 
LY3298176 Solution
Dosage Formulation
Reference lyophilized 
powder in glass vial
Test solution formulation in
a glass vial
Test solution formulation
in a glass vial
Unit Dose Strength(s) / 
Dosage Level(s)
Each vial can deliver 5 mg 
LY3298176
Concentration ranging from
10 mg/mL to 30 mg/mL
Placebo
Route of Administration
Subcutaneous injection
and intravenous infusion
Subcutaneous injection and 
intravenous infusion
Subcutaneous injection
Dosing Instructions
Single-dose administration
Single-dose administration
Single-dose
administration
7.2.
Method of Treatment Assignment
Part A: the treatment to be injected for each period will be determined according to a 
randomization schedule.
Part B:  a fixed, single-arm treatment.
Part C: the treatment to be injected on a given treatment day will be determined according to a 
randomization schedule.
7.2.1. Selection and Timing of Doses
Part A: Subjects will be randomized to 1 of 2 treatment sequences to be administered over 
2 consecutive study periods.  Each treatment period will consist of the reference lyophilized
formulation and a test-solution formulation. The sequence of treatments will be administrated 
according to the randomization schedule. The doses will be administered at approximately the 
same time of the day during both periods. The actual time of all dose administrations will be 
recorded in the subject’s electronic case report form (eCRF). Injections will be administered into 
the SC tissue of the abdominal wall.
Part B: A single, 0.5-mg IV dose of LY3298176 will be administered in the morning following 
an 8-hour, overnight fast. The actual start and stop time of IV dose administration will be 
recorded in the subject’s eCRF.
Part C: Dosing will commence at approximately the same time of day at each dosing instance.
The actual time of all dose administrations will be recorded in the subject’s eCRF. All injections 
will be administered into the SC tissue of the abdominal wall. Injection sites will be alternated 
weekly between 4 sites (ie, right and left upper quadrants and right and left lower quadrants) on 
the abdominal wall.
7.3.
Blinding
Parts A and B are open label. Part C is investigator- and subject-blinded.
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a subject’s treatment assignment is warranted for medical management of the event.  The 
subject’s safety must always be the first consideration in making such a determination.  If the 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 33
LY3298176
investigator decides that unblinding is warranted, it is the responsibility of the investigator to 
promptly document the decision and rationale and notify Lilly as soon as possible.
7.4.
Dose Modification
Part B: An 0.5-mg LY3298176 dose is planned to be administered over 10 minutes to the first 
2 subjects. If vomiting is noted in the first 2 subjects, to the extent that treatment with 
antiemetics and intravenous fluids is required, a reduced dose (0.25 mg) may be administered to 
the next 6 subjects planned in this part. If there are no safety concerns, then, following an 
interim PK analysis, the same planned dose of 0.5 mg will be administered to the next 4 subjects 
enrolled in this part. If, following the interim analysis, it is noted that the LY3298176
concentrations cannot be adequately measured, then a different dose may be considered for an 
additional 6 subjects. 
7.4.1. Management of Intravenous Infusion
7.4.1.1.
Premedication for Infusions
Premedication for the infusions is not planned.  However, if an infusion reaction occurs, 
appropriate medication may be used, as determined by the study investigator(s).  If infusion 
reactions are observed, but a review of the data suggests that dose escalation may continue, 
administration of acetaminophen, 500 to 1000 mg, and/or an antihistamine may be administered 
orally, 30 to 60 minutes prior to the start of infusion for subsequent subjects.
The decision to implement premedication for infusions in subsequent cohorts will be made by 
the investigator and Sponsor, and recorded in the study documentation along with the dose-
escalation decision.
Any premedications given will be documented as a concomitant therapy (see Section 7.7).
7.4.1.2.
Management of Infusion Reactions
There is a risk of infusion reaction with any biological agent; therefore, all subjects should be 
monitored closely.  Symptoms and signs that may occur as part of an infusion reaction include, 
but are not limited to: fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, 
throat irritation, rash, pruritus, myalgia, and dizziness.  
In the event that a significant infusion reaction occurs, the following guidance should be followed:

The investigational product infusion should be slowed (eg, reduce infusion rate by 50%
[ie, an infusion rate of 12 mL/hr becomes 6 mL/hr or slower]) or stopped, depending on 
the symptoms/signs present:
o
If slowed, the infusion should be completed at the slower rate, as tolerated.
o
If determined by the investigator that the infusion should no longer continue, no 
further attempts to dose the subject should be made.

Supportive care should be employed in accordance with the symptoms/signs.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 34
LY3298176

If a subject’s infusion reaction is sufficiently severe to discontinue the infusion, 
subsequent infusions may be administered with premedication, at the discretion of the 
investigator, following agreement with the Lilly clinical research physician (CRP) or 
clinical pharmacologist.

If a subject’s infusion rate is reduced due to an infusion reaction, subsequent infusions 
may be administered, at the discretion of the investigator, following agreement with the 
Lilly CRP or clinical pharmacologist.  If further infusions are administered, the infusion 
rate must not exceed the slowest rate used to complete the infusion on the occasion when 
the infusion reaction occurred.  Premedication may be administered at the discretion of 
the investigator.

If it is determined that the subject should not receive further doses of investigational 
product, the subject should complete AE and other follow-up procedures, per Section 2 of 
this protocol.
If the signs and symptoms indicate that a subject is suffering from possible infection(s), he/she 
will be clinically managed, treated, and followed up until resolution. Any AEs will be recorded,
as appropriate.
7.5.
Preparation/Handling/Storage/Accountability
The investigator (or designee) must confirm that appropriate temperature conditions have been 
maintained, as communicated by the Sponsor, during transit for all investigational product
received, and that any discrepancies are reported and resolved before use of the study treatment.
Only participants enrolled in the study may receive investigational product or study materials, 
and only authorized site staff may supply or administer investigational product.
All investigational product should be stored in an environmentally controlled and monitored 
(manual or automated) area in accordance with the labeled storage conditions, with access 
limited to the investigator and authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance (such as
receipt, reconciliation, and final disposition of records).
7.6.
Treatment Compliance
The investigational product will be administered at the clinical site, and documentation of 
treatment administration will occur at the site.
7.7.
Concomitant Therapy
Subjects should not use over-the-counter or prescription medication, and/or herbal supplements, 
with the exception of vitamin/mineral supplements, any hormone replacement therapy, and/or 
thyroid replacement therapy, within 14 days prior to dosing and for the duration of the study.
The use of topical medication may be permitted if no evidence of chronic dosing with the risk of
systemic absorption exists.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 35
LY3298176
Because LY3298176 may be associated with nausea and vomiting, symptomatic care (eg, 
antiemetic drugs [except 5-hydroxytryptamine 3 antagonists] and antacids) can be used as per 
usual standard of care, but should be avoided if possible. Signs and symptoms of dehydration 
should be evaluated and, if present, appropriately managed. 
Additional drugs are to be avoided during the study, unless required to treat an AE. Any drug 
given for treatment of an AE should be documented as such.
If the need for any other concomitant medication (eg, nonsteroidal anti-inflammatory drugs, 
acetaminophen, or antihistamines) arises, inclusion or continuation of the subject may be at the 
discretion of the investigator, preferably after consultation with a Lilly CRP or clinical 
pharmacologist. Any additional medication used during the course of the study must be 
documented in the eCRF.
7.8.
Treatment after the End of the Study
LY3298176 will not be made available to subjects after the conclusion of the study.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 36
LY3298176
8. Discontinuation Criteria
8.1.
Discontinuation from Study Treatment
Discontinuation of the investigational product for abnormal pancreatic tests and liver function 
tests (LFTs) should be considered by the investigator when a subject meets any of the following 
conditions:

ALT or AST >5X ULN in healthy subjects

ALT or AST >3X ULN sustained for more than 2 weeks in healthy subjects

ALT or AST >3X ULN and TBL >2X ULN or international normalized ratio (INR) >1.5.

ALT or AST >3X ULN with the appearance of fatigue, nausea, vomiting, right upper-
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)

Lipase and/or amylase are confirmed to be ≥3X ULN (please refer to algorithm for 
the monitoring of pancreatic events in Appendix 7)

Drug-related vomiting requiring IV hydration treatment or causing severe distress 
(prevents daily activities and results in no appetite, or requires an emergency department 
visit or hospitalization)
The criteria for enrollment must be followed explicitly.  If a subject who does not meet 
enrollment criteria is inadvertently enrolled, that subject must be discontinued from the 
investigational product, but may be allowed to continue in the study to provide the follow-up 
data.
Subjects who discontinue the investigational product early will have procedures performed, as 
shown in the Schedule of Activities (Section 2).
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the Sponsor or investigator identifies a subject who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the Lilly clinical pharmacologist and the 
investigator to determine if the subject may continue in the study.  If both agree it is medically 
appropriate to continue, the investigator must obtain documented approval from the Lilly clinical 
pharmacologist to allow the inadvertently enrolled subject to continue in the study, with or 
without continued treatment with investigational product.  
8.2.
Discontinuation from the Study
Subjects will be discontinued under the following circumstances:

Enrollment in any other clinical study involving an investigational product, or enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this study.

Participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical practice (GCP).

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 37
LY3298176

Investigator Decision:
o
The investigator decides that the subject should be discontinued from the study.
o
If the subject, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new agent.

Subject Decision
o
The subject (or legal representative) requests to be withdrawn from the study.
8.3.
Subjects Lost to Follow-up
A subject will be considered lost to follow-up if he/she repeatedly fails to return for scheduled 
visits, and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for scheduled visits or who were,
otherwise, unable to be followed up by the site.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 38
LY3298176
9. Study Assessments and Procedures
Section 2 lists the Schedule of Activities, detailing the study procedures and their timing 
(including tolerance limits for timing).
Appendix 2 lists the laboratory tests that will be performed for this study.
Appendix 5 provides a summary of the maximum number and volume of invasive samples, for
all sampling, during the study.
Unless, otherwise, stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards.
9.1.
Efficacy Assessments
Not applicable.
9.2.
Adverse Events
Investigators are responsible for monitoring the safety of subjects who have entered this study,
and for alerting Lilly (or its designee) to any events that seem unusual, even if those events may 
be considered an unanticipated benefit to the subjects.
The investigator is responsible for the appropriate medical care of subjects during the study.
Investigators must document their review of each laboratory safety report.
The investigator remains responsible for following, through an appropriate healthcare option, 
AEs that are serious or, otherwise, medically important, considered related to the investigational 
product or the study, or which caused the subject to discontinue the investigational product 
before completing the study.  The subject should be followed until the event resolves, stabilizes
with appropriate diagnostic evaluation, or is reasonably explained.  The frequency of follow-up 
evaluations of the AE is left to the discretion of the investigator.
After the informed consent form (ICF) is signed, study site personnel will record, via eCRF, the 
occurrence and nature of each subject’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study.  Additionally, site personnel will 
record any change in the condition(s), and the occurrence and nature of any AEs.  
The investigator will interpret and document whether an AE has a reasonable possibility of being 
related to study treatment or a study procedure, taking into account the disease, concomitant 
treatment, or pathologies.  A “reasonable possibility” means that there is a potential cause-and-
effect relationship between the investigational product, study device, and/or study procedure and 
the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condition has 
worsened during the course of the study.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 39
LY3298176
If a subject’s investigational product is discontinued as the result of an AE, study site personnel 
must report this to Lilly (or its designee) via eCRF.
9.2.1. Serious Adverse Events
An SAE is any AE from this study that results in one of the following:

death

initial or prolonged inpatient hospitalization

a life-threatening experience (ie, immediate risk of dying)

persistent or significant disability/incapacity

congenital anomaly/birth defect

important medical events that may not be immediately life-threatening or result in death 
or hospitalization, but that may jeopardize the subjects or may require intervention to 
prevent one of the other outcomes listed in the definition above
Study site personnel must alert the Lilly CRP/clinical pharmacologist (or its designee) of any 
SAE as soon as practically possible.  Additionally, study site personnel must alert Lilly Global 
Patient Safety (or its designee) of any SAE within 24 hours of investigator awareness of the 
event via a Sponsor-approved method.  If alerts are issued via telephone, they are to be 
immediately followed with official notification on study-specific SAE forms.  This 24-hour 
notification requirement refers to the initial SAE information and all follow-up SAE 
information.
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting to the 
Sponsor begins after the subject has signed informed consent and has received investigational 
product.  However, if an SAE occurs after signing informed consent, but prior to receiving 
investigational product, and is considered reasonably possibly related to a study procedure, then 
it must be reported.
Pregnancy (maternal or paternal exposure to investigational product) does not meet the definition 
of an AE.  However, to fulfill regulatory requirements, any pregnancy should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
9.2.1.1.
Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to investigational product or procedure.  Lilly 
has procedures that will be followed for the recording and expedited reporting of SUSARs that 
are consistent with global regulations and the associated detailed guidance.
9.2.2. Complaint Handling
Lilly collects product complaints on investigational products and drug delivery systems used in 
clinical trials in order to ensure the safety of study participants, to monitor quality, and to 
facilitate process and product improvements.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 40
LY3298176
Subjects should be instructed to contact the investigator as soon as possible if they have 
complaints or problems with the investigational product (or drug delivery system), so that the 
situation can be assessed.
9.3.
Treatment of Overdose
For the purposes of this study, an overdose of LY3298176 is considered to be any dose higher 
than the dose assigned through randomization.  Treatment for overdose is supportive care. For 
detailed information, refer to the IB for LY3298176.
9.4.
Safety
9.4.1.Laboratory Tests
For each subject, laboratory tests detailed in Appendix 2 should be conducted, according to the 
Schedule of Activities (Section 2).
9.4.2. Vital Signs
For each subject, vital signs (blood pressure, pulse rate, temperature) measurements should be 
conducted, according to the Schedule of Activities (Section 2).
Blood pressure and pulse rate should be measured after the subject is supine for at least 
5 minutes.
If orthostatic measurements are required, the subject should be supine for at least 5 minutes and 
stand for at least 3 minutes.
If the subject feels unable to stand, supine vital signs only will be recorded. 
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture-induced symptoms.  Additional vital signs may be measured during each study period, if 
warranted.
9.4.3. Electrocardiograms
For each subject, ECGs should be collected, according to the Schedule of Activities (Section 2).  
Any clinically significant findings from ECGs that result in a diagnosis, and that occur after the 
subject receives the first dose of the investigational product, should be reported to Lilly (or its 
designee) as an AE via eCRF.
For each subject, a single12-lead digital ECG will be collected, according to the Schedule of 
Activities (Section 2).  Electrocardiograms must be recorded before collecting any blood 
samples. Subjects must be supine for approximately 5 to 10 minutes before ECG collection, and 
remain supine, but awake, during ECG collection.  Electrocardiograms may be obtained at 
additional times, when deemed clinically necessary.  All ECGs recorded should be stored at the 
investigational site.
Electrocardiograms will be interpreted by a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collection as possible, and ideally while the 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 41
LY3298176
subject is still present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findings be 
identified.  
If a clinically significant finding is identified (including, but not limited to, changes in 
QT/corrected QT [QTc] interval from baseline) after enrollment, the investigator will determine 
whether the subject can continue in the study.  The investigator (or qualified designee) is 
responsible for determining if any change in subject management is needed, and must document
his/her review of the ECG printed at the time of collection.  Any new clinically relevant finding 
should be reported as an AE.
9.4.4. Body Weight
Weight will be measured, as indicated in the Schedule of Activities (Section 2). Subjects will be 
weighed in light clothing at approximately the same time in the morning, before dosing and after 
an overnight fast and evacuation of the bowel and bladder, if possible. During the treatment 
period, weight will be measured twice on each scheduled occasion, with the subject stepping off 
the scale between measurements. Both weight measurements will be recorded in the source 
document and the eCRF. Wherever possible, the same scale will be used for all weight 
measurements throughout the study, and the scale will not be moved or recalibrated.
9.4.5. Safety Monitoring
The Lilly clinical pharmacologist or CRP will monitor safety data throughout the course of the 
study.
Lilly will review SAEs within time frames mandated by company procedures.  The Lilly clinical 
pharmacologist or CRP will periodically review the following data:

trends in safety data

laboratory analytes 

serious and nonserious AEs, including AEs of special interest (GI events, hypoglycemia, 
injection-site reactions, and hypersensitivity reactions) and reported and adjudicated
pancreatitis
When appropriate, the Lilly clinical pharmacologist or CRP will consult with the functionally 
independent Global Patient Safety therapeutic area physician or clinical research scientist.
9.4.5.1.
Hepatic Safety
If a study subject experiences elevated ALT ≥3X ULN, alkaline phosphatase (ALP) ≥2X ULN, 
or elevated TBL ≥2X ULN, liver tests (Appendix 4) should be repeated within 3 to 5 days 
including ALT, AST, ALP, TBL, direct bilirubin, gamma-glutamyl transferase (GGT), and 
creatinine kinase to confirm the abnormality and to determine if it is increasing or decreasing.  
If the abnormality persists or worsens, clinical and laboratory monitoring should be initiated by 
the investigator, based on consultation with the Lilly clinical pharmacologist or CRP.  
Monitoring should continue until levels normalize and/or are returning to approximate baseline 
levels.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 42
LY3298176
Additional safety data should be collected if 1 or more of the following conditions occur: 

elevation of serum ALT to ≥5X ULN on 2 or more consecutive blood tests

elevated serum TBL to ≥2X ULN (except for cases of known Gilbert’s syndrome)

elevation of serum ALP to ≥2X ULN on 2 or more consecutive blood tests 

subject discontinued from treatment due to a hepatic event or abnormality of liver 
tests

hepatic event considered to be a SAE
9.4.6. Hypersensitivity Reactions
All hypersensitivity reactions will be reported by the investigator as either AEs or, if any serious 
criterion is met, as SAEs.  Dosing should be temporarily discontinued in any individual 
suspected of having a severe or serious allergic/hypersensitivity reaction to investigational 
product.  Investigational product may be restarted if, in the opinion of the investigator, the event 
was not related to study drug and when/if it is safe to do so.  If dosing is permanently 
discontinued, the subject should remain in the study, as needed, per medical judgment.
The report of a clinically significant AE of drug reaction or injection-site reaction may prompt 
notification of the Sponsor, clinical photography, and referral for dermatologic evaluation and 
consideration of a skin biopsy and laboratory evaluations (ALT, AST, complete blood count with 
percent eosinophils, and additional immunogenicity testing).
9.4.6.1.
Injection-Site Reactions
If an injection-site reaction is present, it will be fully characterized (including erythema, 
induration, pain, itching, and swelling) and will be closely monitored until resolution.
Investigational site staff will be provided with separate instructions/training on how to
consistently evaluate injection-site reactions and their severity. Photographs of injection-site 
reactions may be taken in a standardized fashion for record-keeping purposes; however, the 
photographs will not be used to evaluate injection-site reaction severity.
9.4.6.1.1. Pain Measurements Using the Visual Analog Scale
Pain measurements will be assessed using a 100-mm validated visual analog scale (VAS) for 
pain.  The VAS is a well-validated tool (Williamson and Hoggart 2005) to assess injection-site 
pain.  The VAS is presented as a 10-cm (100-mm) line, anchored by verbal descriptors, usually 
“no pain” and “worst imaginable pain.”  The subject will be asked to mark the 100-mm line to 
indicate pain intensity at time points according to the Schedule of Activities (Section 2) and as 
clinically indicated.  A staff member will use a caliper to measure the distance from 0 to the 
mark that the subject placed on the VAS, and to record the measurement in the source document.
9.4.7. Glucose Monitoring (Part C)
Subjects will be instructed on how to use the glucose meter provided by the site, and to conduct 
self-blood glucose-monitoring tests; subjects will be also educated on the symptoms of 
hypoglycemia.  Throughout their participation in the study, subjects will monitor blood-glucose 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 43
LY3298176
levels.  Subjects will be provided a diary card and instructed to record blood-glucose results
premeal and at bedtime on at least 2 days per week during the dosing phase of the study, and
whenever the subject experiences symptoms of hypoglycemia. Investigator review of glucose 
results clinically indicative of hypoglycemia is required.
9.4.7.1.
Hyperglycemia and Hypoglycemia Reporting
Episodes of hyperglycemia (fasting plasma/serum glucose >270 mg/dL [15 mmol/L]) or 
hypoglycemia (plasma/serum glucose ≤70 mg/dL [3.9 mmol/L]) will be reported by the 
investigator or designated physician who will be responsible for advising the subject on what 
further actions to take. Additional monitoring may be requested at the investigator’s discretion.
If the fasting plasma/serum glucose during the dosing period exceeds the acceptable level 
defined as hyperglycemia on 3 or more separate days over any 2-week period between screening 
and the end of the dosing period, the subject will be evaluated further at the study site. If fasting 
plasma/serum glucose continues to exceed the acceptable level, the investigational product will 
be discontinued, and treatment with an appropriate antidiabetic agent may be initiated by the 
investigator. If hyperglycemia occurs during the follow-up period, the subject will remain in the 
study until completion of the planned follow-up.
Hypoglycemia episodes will be recorded on specific eCRF pages. Hypoglycemia will be treated 
appropriately by the investigator and additional monitoring of plasma/serum glucose levels may 
be performed. The following categories of the 2017 American Diabetes Association position 
statement on glycemic targets (American Diabetes Association 2017) based on recommendations 
of the International Hypoglycaemia Study Group (IHSG 2017) should be applied for reporting in 
the eCRF and evaluating hypoglycemic events.
The main categories of hypoglycemia are outlined below:
Documented Glucose Alert Level (Level 1): plasma/serum glucose ≤70 mg/dL (3.9 mmol/L)

Documented symptomatic hypoglycemia: with typical symptoms of hypoglycemia.

Documented asymptomatic hypoglycemia: without typical symptoms of
hypoglycemia.

Documented unspecified hypoglycemia: with no information about symptoms of 
hypoglycemia available (also called unclassifiable hypoglycemia).
Documented Clinically Significant Hypoglycemia (Level 2): similar criterion as above, except 
for threshold plasma/serum glucose <54 mg/dL (3.0 mmol/L)

Level 2 documented symptomatic hypoglycemia.

Level 2 documented asymptomatic hypoglycemia.

Level 2 documented unspecified hypoglycemia.
Severe Hypoglycemia (Level 3):

Severe hypoglycemia (in adults): Subjects had altered mental status, and could not assist 
in their own care, or were semiconscious or unconscious, or experienced coma with or
without seizures, and the assistance of another person was to actively administer 
carbohydrate, glucagon, or other resuscitative actions. Plasma/Serum glucose
measurements may not be available during such an event, but neurological recovery

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 44
LY3298176
attributable to the restoration of plasma/serum glucose concentration to normal is
considered sufficient evidence that the event was induced by a low plasma/serum
concentration (plasma/serum glucose ≤70 mg/dL [3.9 mmol/L]).

Severe hypoglycemia requiring medical attention: Severe hypoglycemic events when 
subjects require therapy by healthcare providers (emergency medical technicians, 
emergency room personnel, etc.) are of particular interest to payers. Therefore, some 
clinical trials may want to collect data on this subset of severe hypoglycemia episodes, 
especially if economic outcomes analyses may be based on trial results.
Other Hypoglycemia

Nocturnal hypoglycemia: Any documented hypoglycemic event (including severe 
hypoglycemia) that occurs at night and presumably during sleep. At Lilly, this is 
captured as hypoglycemia that occurs between bedtime and waking. This definition is 
more useful than the commonly used approximately midnight to approximately 6 AM 
definition which does not take subjects’ individual sleep times into consideration, 
and is consistent with the American Diabetes Association recommendations of 
reporting events that occur during sleep (American Diabetes Association 2005). It is 
also important to collect the actual time when a hypoglycemic event occurred to allow 
further characterization of hypoglycemia timing (eg, to allow analysis of frequency of
events occurring across a 24-hr clock). Nocturnal hypoglycemia may occur at severity 
Levels 1, 2, or 3.

Relative hypoglycemia (also referred to as pseudohypoglycemia [Seaquist et al. 2013]):
An event during which typical symptoms of hypoglycemia occur that does not require
the assistance of another person, and is accompanied by plasma/serum glucose 
>70 mg/dL (3.9 mmol/L). The plasma/serum glucose value of patients with chronically 
poor glycemic control can decrease so rapidly that subjects may report symptoms of
hypoglycemia before their plasma/serum glucose concentration falls below 70 mg/dL
(3.9 mmol/L). Events with plasma/serum glucose ≤70 mg/dL should not be 
categorized as relative hypoglycemia. Evaluation and statistical analysis of this 
category is optional. However, if a patient reports a relative hypoglycemia event where
assistance from another person was received or the subject experienced significant 
symptoms, the study team should clarify the circumstances to ensure the event is not a
severe hypoglycemia event, and report it appropriately. 

Probable symptomatic hypoglycemia: Symptoms of hypoglycemia were present, but 
plasma/serum glucose measurement was not reported.

Overall (or total) hypoglycemia: This optional category combines most cases of
hypoglycemia (documented hypoglycemia and probable symptomatic hypoglycemia, 
including severe hypoglycemia). It does not include relative hypoglycemia. Nocturnal
and severe hypoglycemia are special cases of documented or probable hypoglycemia.
If an event of hypoglycemia falls into multiple subcategories, that event should only be
counted once in the category of overall (or total) hypoglycemia.
If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious in the 
eECRF (that is, recorded as an SAE). In the case of a hypoglycemic event (other than severe), 
the actual glucose value, if measured, should be recorded in the eECRF, together with any 

I8F-MC-GPGE(a)Clinical Pharmacology Protocol
Page 45
LY3298176
treatments administered and not be recorded as an AE.Cases of hypoglycemia may be treated 
with foods rich in carbohydrate such as fruit, juice, skim milk, or energy bars.All episodes of 
hypoglycemia that are determined by the investigator to constitute severe hypoglycemia,
according to the definition above,should be reported as SAEs.
9.4.8. Nausea and Vomiting
Nausea and vomiting events are considered AEs of interest,and will be recorded as AEs in the
eCRF. For each event,assessment of severity, duration,and investigator’s opinion of relatedness
to study drug and protocol procedure will be captured.
9.4.9. Elevated Lipase or Amylase
Serum amylase and lipase measurements will be collected as part of the clinical laboratory
testing,at time points specified in the Schedule of Activities (Section 2).Additional
measurements may be performed at the investigator’s discretion. Further diagnostic assessments
will be recommended,as per the algorithm (refer to Appendix 7) for the monitoring of pancreatic
events whenever lipase and/or amylase is confirmed to be ≥3XULN at any visit
postrandomization, even if the subject is asymptomatic.
9.4.10.Immunogenicity Assessments
At the visits and times specified in the Schedule of Activities(Section 2), venous bloodsamples 
will be collected to determine antibody production against LY3298176.  To interpret the results 
of immunogenicity, a PK sample will be collected at the same time points. All samples for 
immunogenicity should be taken predose,when applicable. In the event of drug hypersensitivity 
reactions (immediate or nonimmediate), additional samples will be collectedas close to the onset 
of the eventas possible, at the resolution of the event, and 30 days following the event.  
Instructions for the collection and handling of blood samples will be provided by the sponsor.  
The actual date and time (24-hour clock time) of each sampling will be recorded.  
Immunogenicity will be assessed by a validated assay designed to detect ADAs in the presence 
of LY3298176at a laboratory approved by the Sponsor. Positive ADA samples may be 
evaluated for neutralizing antibodies to LY3298176. Positive ADA samples may also be tested 
for cross-reactivity with native GLP-1 and GIP, and,if positive, then,additional testing for 
neutralizing antibodies against native GLP-1 may also be conducted.  
All subjects will have an ADA sample measured at early discontinuation or at the follow-up visit
(date of visit outlined in the Schedule of Activities [Section 2]
CCI
).A risk-based approach will be 
used to monitor subjects who have clinically significant treatment-emergent ADAs (TE-ADAs)
at the last visit.
 
 
 
 

I8F-MC-GPGE(a)Clinical Pharmacology Protocol
Page 46
LY3298176
 
 
A PK sample may be collected at the 
follow up immunogenicity assessment(s),if warranted and agreed upon by the investigator and 
Sponsor.
Every attempt should be made to contact subjectsfor the follow-up immunogenicity assessment; 
however, if subjectsare unwilling or unable to return for the visit, this is not considered a 
protocol violation.
Subjectsfollowed for at least 1 year since last dose who have not returned to baseline, as defined 
above, will be assessed for safety concerns and, if no clinical sequelae arerecognized by the 
clinical team, no further follow-up will be required.Subjectswho have clinical sequelae that are 
considered potentially related to the presence of TE-ADAsmay also be asked to return for 
additional follow-up testing.
Samples will be retained for a maximum of 15 years after the last subject visit, or for a shorter 
period if local regulations and ethical review boards (ERBs) allow,at a facility selected by the 
Sponsor.  The duration allows the Sponsor to respond to future regulatory requests related to 
LY3298176.  Any samples remaining after 15 years will be destroyed.
9.5. Pharmacokinetics
At the visits and times specified in the Schedule of Activities (Section 2), venous blood samples
of approximately 3mL each will be collected to determine the plasma concentrations of
LY3298176.A maximum of 3 samples may be collected at additional time points during the
study,if warranted and agreed upon byboth the investigator and Sponsor.Instructions for the 
collection and handling of blood samples will be provided by the Sponsor.The actual date and 
time (24-hour clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will be analyzed at a laboratory approved by the Sponsor,and stored at a facility
designated by the Sponsor.Concentrations of LY3298176 will be assayed using a validated 
liquid chromatography massspectrometry (LC/MS) method.  Analyses of samples collected 
from placebo-treatedsubjects are not planned.Bioanalytical samples collected to measure 
investigational product concentrations will beretained for a maximum of 1 year following last 
subject visit for the study. 
9.6. Pharmacodynamics
CCI
Not applicable.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 47
LY3298176
9.7.
Genetics
A blood sample will be collected for pharmacogenetic analysis, as specified in the Schedule of 
Activities (Section 2), where local regulations allow.  
Samples will not be used to conduct unspecified disease or population genetic research, either 
now or in the future.  Samples will be used to investigate variable exposure or response to
LY3298176, and to investigate genetic variants thought to play a role in T2DM.  Assessment of 
variable response may include evaluation of AEs or differences in efficacy.  
All samples will be coded with the subject number.  These samples and any data generated can 
be linked back to the subject only by the investigative site personnel.  
Samples will be retained for a maximum of 15 years after the last subject visit, or for a shorter 
period if local regulations and/or ERBs/investigational review board (IRBs) impose shorter time 
limits, for the study at a facility selected by Lilly. This retention period enables use of new 
technologies, response to regulatory questions, and investigation of variable response that may 
not be observed until later in the development of LY3298176 or after LY3298176 is 
commercially available.  
Molecular technologies are expected to improve during the 15-year storage period and, therefore,
cannot be specifically named.  However, existing approaches include whole genome or exome 
sequencing, genome-wide association studies, multiplex assays, and candidate gene studies.  
Regardless of technology utilized, data generated will be used only for the specific research 
scope described in this section. 
9.8.
Biomarkers
Not applicable.
9.9.
Health Economics
Not applicable.

I8F-MC-GPGE(a)Clinical Pharmacology Protocol
Page 48
LY3298176
10. Statistical Considerations and Data Analysis
10.1.Sample SizeDetermination
Approximately20 healthy subjects may be enrolled in Part A in order that at least 16 subjects 
complete Part A.  Up to 10 subjects will be enrolled in Part B in order that at least 6subjects 
complete Part B.  Approximately 16healthy subjectsmay be enrolled in Part C in order that at 
least 12subjectscomplete Part C(in a 3LY3298176:1placeboratio).
For each study part, any dropout may be replaced so that the targeted numbers of subjects for 
safety review and data collection maybe achieved.  The replacement subjectwill be assigned to 
receivethe treatment of the dropout.
Part A:
 
 
PartsB and C:  The sample size is customary for Phase 1 studies evaluating safety and PK.  
Thesample sizes are not based on statistical calculations.  The sample sizes for each part of the 
study are considered sufficient to evaluate the primary objectives ofthis study.
10.2.Populations for Analyses
10.2.1.Study Participant Disposition
A detailed description of subject disposition will be providedat the end of the study. 
Allsubjects who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported.  If known, a reason for their discontinuation will be 
given.
10.2.2.Study Participant Characteristics
The subject’s age, sex, weight, height, or other demographic characteristics will be recorded and
may be used in the PK, PD, and safety analyses as quantitative or classification variables.
10.3.Statistical Analyses
CCI
Statistical analysis of this study will be the responsibility of Eli Lilly and Company (or its 
designee).
Pharmacokineticanalyses will be conducted on data from all subjectswho receiveat least 1dose 
of the investigational productand who have evaluable PK.  
Safety analyses will be conducted for all enrolled subjects, whether or not they completed all 
protocol requirements.
Unless,otherwise,noted, all tests of treatment effects will be conducted at a 2-sided alpha level 
of0.1, and 90% CIs will be calculated.

I8F-MC-GPGE(a)Clinical Pharmacology Protocol
Page 49
LY3298176
Additional exploratory analyses of the data will be conducted,as deemed appropriate.  
Studyresults may be pooled with the results of other studies for post-hoc analyses.  
10.3.1.Safety Analyses
10.3.1.1.Clinical Evaluation of Safety
All investigational productand protocol procedure AEs will be listed, and,if the frequency of 
events allows, safety data will be summarized using descriptive methodology.
The incidence of symptoms for each treatment will be presented by severity and by association 
with investigational product,as perceived by the investigator.  Symptoms reported to occur 
before the first study drug dosingwill be distinguished from those reported as new or increased 
in severity during the study.  Each symptom will be classified by the most suitable term from the 
Medical Dictionary for Regulatory Activities.
The number of investigational product-related SAEs will be reported.
10.3.1.2.Statistical Evaluation of Safety
Safety parameters that will be assessed include: safety laboratory parameters,vital signs,and 
ECG parameters.  The parameters will be listed. Continuous safety variables will be summarized 
using descriptive statistics.Categorical safetyvariables will be summarized using countand 
percentage.  Vital signs data will be analyzed and summarized for each Part.  Body weight data 
will be summarized.
Additional analysis will be performed,if warranted,upon review of the data.
10.3.1.3.Injection Site Reaction
For Part A and Part C, incidence of erythema, induration, pain, itching, and swelling will be 
listed and summarized by treatment.
The post-injection pain score will be summarized by treatment.  Additional analyses may be 
performed,if appropriate.
10.3.2.PharmacokineticAnalyses
10.3.2.1.Pharmacokinetic Parameter Estimation
Pharmacokineticparameter estimates for LY3298176 will be calculated by standard 
noncompartmentalmethods of analysis. The primary parameters for analysis will be: Cmax, and 
AUCfLY3298176for PartsA, B,and C of the study. Other parameters, such as half-life, 
apparent clearance, and apparent volume ofdistribution, may be reported, as appropriate. 
10.3.2.2.Pharmacokinetic Statistical Inference
10.3.2.2.1.Part A
To assess the relative bioavailability of a single SC dose of LY3298176 administered as a 
solution formulation (test),compared to a lyophilizedformulation (reference), AUC from time 
zero to infinity (AUC0-∞), AUC from time zero to thetime of last measured concentration 
(AUC0-tlast)and C
maxwill be log-transformed and analyzed using a linear mixed effects model 

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 50
LY3298176
with treatment, period, and sequence as fixed effects and subject as a random effect. The 
difference in least squares means (LSMeans) between the test formulation and reference
formulation for each parameter will be exponentiated to yield ratios of geometric LSMeans and 
their corresponding 90% CIs. Time to maximum observed concentration will be analyzed using 
a nonparametric method. The Wilcoxon rank-sum test will be performed.  Median difference 
and 90% CI will be reported.
10.3.2.2.2.Part B
No formal statistical analysis will be performed for the IV formulation evaluation part of the 
study. A descriptive summary of PK parameters will be reported.
10.3.2.2.3.Part C
A descriptive summary of PK parameters, by treatment, will be presented.
10.3.3. Evaluation of Immunogenicity
The frequency and percentage of subjects with preexisting ADAs, ADAs at any time 
postbaseline, and TE-ADAs to LY3298176 will be tabulated. Correspondingly, the frequency 
and percentage of subjects with preexisting or treatment-emergent neutralizing antibodies, and/or 
cross-reacting antibodies to LY3298176 may be tabulated.
The relationship between the presence of antibodies to LY3298176 and the PK parameters and
safety (such as AEs, injection site reactions, formulation, and/or route of administration) may be 
assessed.
10.3.4. Data Review during the Study
An interim analysis is planned after dosing 2 subjects in Part B of the study.
The possible outcomes following IV administration of a 0.5-mg dose of LY3298176 over 
10 minutes are:

LY3298176 tolerability is adequate; LY3298176 concentrations are measurable in the 
2 subjects.

LY3298176 tolerability is inadequate. To improve tolerability, the dose of LY3298176 
may be reduced to 0.25 mg, administered over 10 minutes.

LY3298176 tolerability is adequate; however, if LY3298176 concentrations cannot be 
adequately quantified, then a dose adjustment may be considered. 
Following completion of Parts A and B of this study, an interim database lock may be 
performed.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 51
LY3298176
11.
References
[ADA] American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a
report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care.
2005;28(5):1245-1249.
[ADA] American Diabetes Association. 2017 Standards of medical care in diabetes: glycemic 
targets position statement. Diabetes Care. 2017:40(Suppl 1):S48-S56. Available at:
https://doi.org/10.2337/dc17-S009. Accessed August 22, 2017.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 
2007;132(6):2131-2157.
Dungan KM, Povedano ST, Forst T, González JG, Atisso C, Sealls W, Fahrbach JL. 
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with 
type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 
2014;384(9951):1349-1357.
Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of 
once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin 
and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241-2249.
Herbst R, Bolton W, Shariff A, Green JB. Cardiovascular outcome trial update in diabetes: new 
evidence, remaining questions. Curr Diab Rep. 2017;17(9):67.
[IHSG] International Hypoglycaemia Study Group. Glucose concentrations of less than 
3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the 
American Diabetes Association and the European Association for the Study of Diabetes. 
Diabetes Care 2017;40(1):155-157. Available at: https://doi.org/10.2337/dc16-2215. Accessed
January 10, 2016.
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of 
dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide 
clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev.
2016;32(8):776-790
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, 
Matthews DR; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, 
glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD 
(liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, Jensen CB, 
Atkin SL; Study 1821 Investigators. A phase 2, randomized, dose-finding study of the novel 
once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label 
liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231-241.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, 
Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the 
American Diabetes Association and the Endocrine Society. Diabetes Care. 
2013;36(5):1384-1395.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 52
LY3298176
Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin 
Nurs. 2005;14(7):798-804.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 53
LY3298176
Appendix 1.
Abbreviations and Definitions

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 54
LY3298176
Term
Definition
ADA
antidrug antibody
AE
adverse event:  any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP
alkaline phosphatase
ALT
alanine aminotransferase
assent
Agreement from a child or other individual who is not legally capable of providing consent, 
but who can understand the circumstances and potential risks involved in participating in a 
study (required by some institutional review boards [IRBs]/ethical review boards [ERBs]). 
AST
aspartate aminotransferase
AUC
area under the drug plasma concentration versus time curve
AUC(0-∞)
area under the drug plasma concentration versus time curve from time zero to infinity
AUC(0-tlast)
area under the drug plasma concentration versus time curve from time zero to the time of 
last measured concentration
blinding
A procedure in which one or more parties to the study are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient/subject is not, or vice versa, or when the Sponsor is aware of the 
treatment but the investigator and/his staff and the patient/subject are not.  A double-blind 
study is one in which neither the patient/subject nor any of the investigator or Sponsor staff 
who are involved in the treatment or clinical evaluation of the subjects are aware of the 
treatment received
BP
blood pressure
CBC
complete blood count
CI
confidence interval
CIOMS
Council for International Organizations of Medical Sciences
Cmax
maximum observed (peak) concentration
CNS
central nervous system
complaint
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 55
LY3298176
Term
Definition
compliance
Adherence to all the study-related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation
A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CPK
creatinine phosphokinase
CRP
clinical research physician:  individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CRU
clinical research unit
CSE
clinically significant effect
CT
computed tomography
CV
coefficient of variation
DBP
diastolic blood pressure
DPP-IV
dipeptidyl peptidase IV
ECG
electrocardiogram
eCRF
electronic case report form
enroll
The act of assigning a patient/subject to a treatment.  Patients/Subjects who are enrolled in 
the study are those who have been assigned to a treatment.
enter
Patients/Subjects entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB
ethical review board
FOIA
Freedom of Information Act
FSH
follicle-stimulating hormone
GCP
good clinical practice
GGT
gamma-glutamyltransferase
GI
gastrointestinal
GIP
glucose-dependent insulinotropic polypeptide

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 56
LY3298176
Term
Definition
GLP-1
glucagon-like peptide 1
GLP-1 RA
glucagon-like peptide 1 receptor agonist
HIV
human immunodeficiency virus
IB
Investigator’s Brochure
ICF
informed consent form
ICH
International Conference on Harmonisation
Ig
immunoglobulin
informed consent
A process by which a patient/subject voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study that 
are relevant to the patient/subject’s decision to participate.  Informed consent is documented 
by means of a written, signed and dated informed consent form.  
INR
international normalized ratio
interim analysis
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
Investigational 
product
A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator
A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IRB
institutional review board
IV
intravenous administration
LC/MS
liquid chromatography-mass spectrometry
Legal 
Representative
An individual or judicial or other body authorized under applicable law to consent, on behalf of 
a prospective a patient/subject, to the a patient/subject’s participation in the clinical study.
LFT
liver function test
LSMean
least squares mean
MRI
magnetic resonance imaging
NOAEL
no-observed-adverse-effect level

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 57
LY3298176
Term
Definition
open-label
A study in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PD
pharmacodynamic
PK
pharmacokinetic
PR
pulse rate
QTc
corrected QT interval
QW
once weekly administration
randomize
the process of assigning subjects/patients to an experimental group on a random basis
RBC
red blood cell
SAE
serious adverse event
SBP
systolic blood pressure
SC
subcutaneous administration
screen
The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
SUSARs
suspected unexpected serious adverse reactions 
T
temperature
T2DM
type 2 diabetes mellitus
TBL
total bilirubin level
TE-ADA
treatment-emergent antidrug antibody
TEAE
treatment-emergent adverse event:  any untoward medical occurrence that emerges during a 
defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship with this treatment
TG
triglyceride
ULN
upper limit of normal
US
United States
USP
United States Pharmacopoeia
VAS
Visual Analog Scale
WBC
white blood cell

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 58
LY3298176
Appendix 2.
Clinical Laboratory Tests
Clinical Laboratory Tests
Hematology
Clinical Chemistry (Fasting)
Hematocrit
Sodium
Hemoglobin
Potassium
Erythrocyte count (RBC)
Bicarbonate
Mean cell volume
Chloride
Mean cell hemoglobin
Serum creatinine
Mean cell hemoglobin concentration
Calcium
Leukocytes (WBC)
Phosphorus
Absolute counts of: 
Glucose, fasting
Neutrophils
Blood urea nitrogen
Lymphocytes
Uric acid
Monocytes
Total protein
Eosinophils
Albumin
Basophils
Total bilirubin
Platelets
Alkaline phosphatase
Alanine aminotransferase
Urinalysis
Aspartate aminotransferase
Specific gravity
Lipase, fasting
pH
Amylase
Protein
Triglycerideb
Glucose
Total cholesterolb
Ketones
Bilirubin
Serologyc
Urobilinogen
Follicle-stimulating hormonea
Blood
Hepatitis B surface antigen
Leukocytes
Hepatitis C antibody
Microscopya
HIV antibody
Pregnancy test (urine, serum) d
Drug and alcohol screene
Abbreviations:  HIV = human immunodeficiency virus; RBC = red blood cell; WBC = white blood cell.
Note:  Results of these assays will be validated by the central or local laboratory at the time of testing.  Additional 
tests may be performed or autocalculated by the laboratory as part of its standard panel that cannot be removed.  
Some of the above parameters are calculated from measured values.  Omission of calculated values will not be 
considered as a protocol violation.
a
If clinically indicated, per investigator’s discretion.
b
Triglyceride and total cholesterol concentrations in the safety panel will not be required on the days that the lipid 
panel is performed.
c
At screening only (unless previously performed within the last 6 months with reports available for review).
d
Pregnancy tests (females, as appropriate) will be performed at the investigator’s discretion.
e
Drug screen and ethanol level may be repeated prior to admission to the clinical research unit and at other times 
indicated in the Schedule of Activities (Section 2).
f
Performed at a local laboratory only at site(s) located in the United States.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 59
LY3298176
Appendix 3.
Study Governance, Regulatory, and 
Ethical Considerations
Informed Consent
The investigator is responsible for:

Ensuring that the subject understands the nature of the study, the potential risks and 
benefits of participating in the study, and that his/her participation is voluntary.

Ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the informed consent form
(ICF) prior to the performance of any protocol procedures and prior to the administration 
of investigational product.

Answering any questions, the subject may have throughout the study, and sharing, in a 
timely manner, any new information that may be relevant to the subject’s willingness to 
continue his/her participation in the study.

Providing a copy of the ICF to the participant or the participant’s legal representative,
and retaining a copy on file.
Recruitment
Lilly (or its designee) is responsible for the central recruitment strategy for subjects.  Individual 
investigators may have additional local requirements or processes.  Study-specific recruitment 
material should be approved by Lilly.
Ethical Review
The investigator must give assurance that the ethical review board (ERB) was properly 
constituted and convened as required by International Conference on Harmonisation (ICH)
guidelines and other applicable laws and regulations.
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site(s).  Lilly (or its representatives) must approve the ICF 
before it is used at the investigative site(s). All ICFs must be compliant with the ICH guideline 
on good clinical practice (GCP).
The study site’s ERB(s) should be provided with the following:

Current Investigator’s Brochure (IB) and updates during the course of the study

Informed consent form

Relevant curricula vitae

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 60
LY3298176
Regulatory Considerations
This study will be conducted in accordance with the protocol and with:
1) consensus ethics principles derived from international ethics guidelines, 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines 
2) applicable ICH GCP Guidelines 
3) applicable laws and regulations
Some of the obligations of the Sponsor will be assigned to a third party organization.
Protocol Signatures
The Sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his/her knowledge, the protocol accurately describes the planned design and conduct of the 
study.  
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative.
Final Report Signature
The investigator (or designee) will sign the clinical study report for this study, indicating 
agreement with the analyses, results, and conclusions of the report.
The Sponsor’s responsible medical officer and statistician will sign/approve the final clinical 
study report for this study, confirming that, to the best of his/her knowledge, the report 
accurately describes the conduct and results of the study.
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly (or its representatives) will do the 
following:

Provide instructional material to the study sites, as appropriate.

Provide training to instruct the investigators and study coordinators.  This training will 
give instruction on the protocol, the completion of the case report forms (CRFs), and 
study procedures.

Make periodic visits to the study site.

Be available for consultation, and stay in contact with the study site personnel by mail, 
telephone, and/or fax.

Review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collection.

Conduct a quality review of the database.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 61
LY3298176
In addition, Lilly (or its representatives) will periodically check a sample of the subject data 
recorded against source documents at the study site.  The study may be audited by Lilly and/or 
regulatory agencies at any time.  Investigators will be given notice before an audit occurs.
The investigator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the investigator will provide the Sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to the original source 
documents.
Data Collection Tools/Source Data
An electronic data capture system will be used in this study.  The site must define and retain all 
source records, and must maintain a record of any data where source data are directly entered 
into the data capture system.
Data Protection
Data systems used for the study will have controls and requirements in accordance with local 
data protection law.  
The purpose and use of subject personal information collected will be provided in a written 
document to the subject by the Sponsor.
Study and Site Closure
Discontinuation of Study Sites
Study site participation may be discontinued if Lilly (or its designee), the investigator, or the 
ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons 
consistent with applicable laws, regulations, and GCP.
Discontinuation of the Study
The study will be discontinued if Lilly (or its designee) judges it necessary for medical, safety, 
regulatory, or other reasons consistent with applicable laws, regulations, and GCP.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 62
LY3298176
Appendix 4.
Hepatic Monitoring Tests for Treatment-
Emergent Abnormality
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality, and 
may be required in follow-up with subjects in consultation with Lilly (or its designee clinical 
research physician [CRP]).
Hepatic Monitoring Tests
Hepatic Hematologya
Haptoglobina
Hemoglobin
Hematocrit
Hepatic Coagulationa
RBC
Prothrombin Time
WBC
Prothrombin Time, INR
Neutrophils
Lymphocytes
Hepatic Serologiesa,b
Monocytes
Hepatitis A antibody, total
Eosinophils
Hepatitis A antibody, IgM
Basophils
Hepatitis B surface antigen
Platelets
Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistrya
Hepatitis C antibody
Total bilirubin
Hepatitis E antibody, IgG
Conjugated bilirubin
Hepatitis E antibody, IgM
Alkaline phosphatase
ALT
Anti-nuclear antibodya
AST
Alkaline Phosphatase Isoenzymesa
GGT
CPK 
Anti-smooth muscle antibody (or anti-actin 
antibody)a
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cells; WBC = white blood cells.
a
Assayed by Lilly-designated or local laboratory.
b
Reflex/Confirmation dependent on regulatory requirements and/or testing availability.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 63
LY3298176
Appendix 5.
Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling (screening, safety laboratories, and bioanalytical assays) during the study.  
Protocol I8F-MC-GPGE Sampling Summary Part A
Type of Sample
Volume per Sample
(mL)
Number of Samples 
per Subject
Total Volume
(mL)
Screening testsa
17.0
1
17.0
Clinical laboratory testsa
6.5
6
39.0
Pharmacokinetics
3.0
29
87.0
Immunogenicity
6.0
6
36.0
Genetic
10.0
1
10.0
Loss by use of indwelling, 
intravenous cannula
1.0
3
3.0
Total:
192.0
a
Additional samples may be drawn, if needed, for safety purposes.
Protocol I8F-MC-GPGE Sampling Summary Part B
Type of Sample
Volume per Sample
(mL)
Number of Samples 
per Subject
Total Volume
(mL)
Screening testsa
17.0
1
17.0
Clinical laboratory testsa
6.5
4
26.0
Pharmacokinetics
3.0
23
69.0
Immunogenicity
6.0
4
24.0
Genetic
10.0
1
10.0
Loss by use of indwelling, 
intravenous cannula
1.0
9
9.0
Total:
155.0
a
Additional samples may be drawn, if needed, for safety purposes.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 64
LY3298176
Protocol I8F-MC-GPGE Sampling Summary Part C
Type of Sample
Volume per Sample
(mL)
Number of Samples 
per Subject
Total Volume
(mL)
Screening testsa
17.0
1
17.0
Clinical laboratory testsa
6.5
3
19.5
Pharmacokinetics
3.0
21
63.0
Immunogenicity
6.0
4
24.0
Pharmacogenomic
10.0
1
10.0
Loss by use of indwelling, 
intravenous cannula
1.0
6
6.0
Total:
139.5
a
Additional samples may be drawn, if needed for safety, purposes.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 65
LY3298176
Appendix 6.
Clinically Significant Adverse Effects
The following table summarizes the type and severity of symptoms, clinical signs, and clinical 
laboratory findings that may qualify as a clinically significant effect (CSE).  These are intended 
as a guideline to the investigator(s), not as a set of absolute criteria.  The underlying principle is 
to define a level of moderate-to-severe abnormality in safety findings that could cause harm to 
health, and would preclude further dosing of a subjects who experiences this effect.  Safety 
parameters not included in this table may be interpreted in a similar fashion, according to 
investigator judgment.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 66
LY3298176
Clinically Significant Adverse Effects
Parameter
CSE level
Symptoms
Severe hypoglycemia
One episode of severe hypoglycemia defined as low blood glucose with mental 
status impairment severe enough to require thirdparty assistance.
Dizziness/hypotension
Orthostatic CNS symptoms (dizziness, confusion) that are not vasovagal responses 
to provocative stimuli (eg, phlebotomy, nausea, bowel or bladder function), and are 
associated with orthostatic SBP decrease >20 mmHg or DBP decrease >10 mmHg 
or heart rate >105 bpm for >3 hours.
Sensorium
Disorientation to time, place, or identity; any abnormal ideation.
Mood
Feelings of grief or loss that interfere with study procedures or activities of daily 
living; any suicidal ideation.
Headache/Pain
Any focal or generalized head pain that disrupts normal activities, and is not 
responsive to medical therapies.
Pruritus
Generalized itching over >24 hours that is unresponsive to oral antihistamine.
Signs
SBP
>30 mmHg increase from baseline values and an absolute level >190 mmHg.
DBP
>20 mmHg increase from baseline values and an absolute level >115 mmHg.
Heart rate
Resting (sitting or recumbent) >120 bpm.
Cardiac Rhythm
Any rhythm other than sinus rhythm, mild sinus bradycardia, or mild sinus 
tachycardia.
QTc
>500 msec or >60 msec increase from baseline value.
QRS morphology
Significant prolongation of QRS interval or new onset of bundle branch block.
Tremor
Readily visible tremor during normal movement, deemed unrelated to 
hypoglycemia.
Reflexes
New onset of clonic reflexes.
Clinical Laboratory
(confirmed by repeat measurements within 48 hours)
Hemoglobin
Absolute value <10 g/dL and >2 g/dL reduction from baseline.
Neutropenia
Absolute neutrophils <1500/μL and >1000 L decrease from baseline.
Lymphopenia
Absolute lymphocyte count <800/μL and >500/L decrease from baseline.
Platelet count
<75,000/μL and >50,000/L decrease from baseline.
Creatinine
>2 mg/dL and >0.5 mg/dL increase from baseline value.
Urea
>8 mmol/L and >3 mmol/L increase from baseline values.
ALT
>5-fold above laboratory reference upper limit value.
AST
>5-fold above laboratory reference upper limit value.
Bilirubin (total)
>1.5-fold above laboratory reference upper limit value.
Potassium
<2.5 or >5.5 mEq/L and >0.5 mEq/L change from baseline value.
Sodium
<130 or >150 mEq/L and >10mEq/L change from baseline value.
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CNS = central nervous system, 
CSE = clinically significant effect, DBP = diastolic blood pressure, QTc = corrected QT interval; SBP = systolic 
blood pressure.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 67
LY3298176
Appendix 7.
Pancreatic Monitoring
Glucagon-like peptide 1 (GLP-1) agonists have been associated with a possible risk of acute 
pancreatitis.  In 2006, the United States (US) prescribing information for exenatide was revised 
to include the event of pancreatitis.  In 2007, the US prescribing information for this medication 
was amended to include pancreatitis under “Precautions.”  Epidemiologic studies have indicated 
that there is an increased incidence and prevalence of pancreatitis in persons with type 2 diabetes 
mellitus (T2DM).
To enhance understanding of the natural variability of pancreatic enzymes in the T2DM 
population and, in order to assess for any potential effects of LY3298176 on the exocrine 
pancreas, amylase and lipase values will be monitored in all current and future clinical trials with 
LY3298176.
Additional monitoring will be requested for amylase or lipase values ≥3X the upper limit of 
normal (ULN) at any visit after randomization, even in asymptomatic subjects (see figure 
below).  Lipase and amylase may also be obtained at any time during the clinical trials for any 
patient/subject suspected of having symptoms suggestive of pancreatitis (such as severe 
gastrointestinal [GI] signs and/or symptoms), at the investigator’s discretion.
Acute pancreatitis is an adverse event (AE) defined as an acute inflammatory process of the 
pancreas that may also involve peripancreatic tissues and/or remote organ systems.  
The diagnosis of acute pancreatitis requires 2 of the following 3 features:

abdominal pain characteristic of acute pancreatitis

serum amylase and/or lipase >3X ULN

characteristic findings of acute pancreatitis on computed tomography scan or 
magnetic resonance imaging
Most subjects with acute pancreatitis experience abdominal pain that is located generally in the 
epigastrium, and radiates to the back in approximately one-half of the cases.  The pain is often 
associated with nausea and vomiting.  However, experience with GLP-1 agonists has 
demonstrated that some subjects asymptomatic for classic pancreatitis may demonstrate 
significant elevations of lipase and/or amylase.  For subjects considered by investigators to be 
asymptomatic for pancreatitis, but whose value(s) for lipase and/or amylase are ≥3X ULN, an 
algorithm is in place to follow these subjects safely and to quickly reach (or not reach) a 
diagnosis of pancreatitis.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 68
LY3298176
Abbreviations:  CBC = complete blood count; CT = computed tomography; LFTs = liver function 
tests; MRI = magnetic resonance imaging.
Pancreatic Enzymes:  Safety Monitoring Algorithm
In Patients without Symptoms of Pancreatitis1,2
Follow this algorithm when the value(s) for serum amylase and/or lipase are = 3x upper limit of normal (ULN)
Test A/L every 4 Weeks 
(More Frequently if Protocol Visit  
Schedule is < 4 weeks)
Negative Imaging Results
Stop Injectable Study Drug5
Consult for Assessment and Management 
Assess for Causes of Pancreatitis 
Notify Lilly
Retest within 24 - 72 hours
Send sample to Laboratory
Amylase and/or Lipase (A/L3) = 3X ULN
A/L Not Decreasing
4.  Abdominal imaging is most valuable when performed 
at the time of elevated enzyme values.  If in the opinion 
of the radiologist or investigator, it is safe for the 
patient/subject to receive contrast, an enhanced 
abdominal CT is preferred. MRI is also an acceptable 
imaging modality.
3. A/L = amylase and/or lipase. Either or both 
enzymes can be used to meet the algorithm criteria.   
5. At a minimum, order a CBC and a pancreatic 
panel (which includes LFTs, calcium and 
triglycerides). Record all concomitant 
medications.
A/L Decreasing
Repeat Abdominal Imaging4
as Soon as Possible After 
Confirmation of Laboratory Values  
1. Symptomatic – related primarily to abdominal pain 
consistent with pancreatitis; however, in the opinion of 
the investigator severe nausea and vomiting plus
other symptoms consistent with pancreatitis may be
considered symptomatic as well.  
2. If in the opinion of the investigator, the patient 
has symptoms of acute pancreatitis:
(a) Stop injectable study drug 
(b) Consult for assessment and management 
(c) Assess for causes of pancreatitis 
(d) Notify Lilly
If A/L = 3X ULN, perform 
Abdominal Imaging4
Stop Injectable Study Drug5
Consult for Assessment and Management 
Assess for Causes of Pancreatitis
Notify Lilly
Test A/L Every 4 Weeks Until 
A/L = 3X ULN, 
Then Follow Protocol Schedule
Positive Imaging Results
Negative Imaging Results
Positive Imaging Results
Test A/L Every 4 Weeks Until 
A/L = 3X ULN, 
Then Follow Protocol Schedule
5
5

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 69
LY3298176
Subjects diagnosed with pancreatitis will be discontinued from the study.  Investigators will be 
responsible for following, through an appropriate healthcare option, these pancreatitis AEs until 
the events resolve or are explained.  Adverse events that meet the diagnostic criteria of acute 
pancreatitis will be captured as serious adverse events (SAEs).  For all other pancreatic AEs 
(such as idiopathic or asymptomatic pancreatic enzyme abnormalities), the investigator will be 
responsible for determining the seriousness of the event (AE or SAE) and the relatedness of the 
event to study drug.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 70
LY3298176
Appendix 8.
Contraceptive Methods
Male subjects with female partners of childbearing potential will be required to use a condom in 
conjunction with a spermicidal gel, foam, cream, or suppository.  In addition, the female partner, 
as well as female subjects of childbearing potential, will be requested to use an additional 
effective form of contraception, which can be any of the following:

female condom with spermicide

diaphragm with spermicide

cervical sponge

cervical cap with spermicide

combined oral contraceptive pill and mini-pill

NuvaRing

implantable contraceptives

injectable contraceptives (such as Depo-Provera)

intrauterine device (such as Mirenaand ParaGard)

true abstinence, when in line with the preferred and usual lifestyle of the patient
Men who have had a vasectomy with appropriate post-vasectomy documentation of the absence 
of sperm in the ejaculate are not required to use contraception.  In addition, Inclusion 
Criterion 1b provides a specific definition of women not of childbearing potential; these subjects 
will not be required to use contraception.  Male subjects with a female partner meeting the 
definition of a woman not of childbearing potential will not be required to use contraception.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 71
LY3298176
Appendix 9.
Protocol Amendment I8F-MC-GPGE(a) 
Summary Pharmacokinetics, Safety, and Tolerability of a 
Solution Formulation of LY3298176 in Healthy Subjects
Overview
Protocol I8F-MC-GPGE(a) Pharmacokinetics, Safety, and Tolerability of a Solution Formulation 
of LY3298176 in Healthy Subjects has been amended.  The new protocol is indicated by 
Amendment (a) and will be used to conduct the study in place of any preceding version of the 
protocol.
The overall changes and rationale for the changes made to this protocol are as follows:

Part C of the protocol has been amended to remove any clinical activities occurring on 
Day -2.  

Reference to a study period in Part B of the protocol is misleading.  Language in the 
protocol referencing a study period is removed.

Clarify that clinical assessments will be taken on Day 92 as part of follow-up activities 
rather than Day 84 for Part C.

Clarify that patients will return to the CRU for study days 35-37 inclusive consistent with 
the Schedule of Activities for Part A.

Clarify that patients will be admitted to the CRU on Day -1 in order to fulfill the 
completion of study assessments scheduled to occur on Day -1.

Added descriptor for each Part A – C to the top row for each SoA page to facilitate ease 
of use

Clarified that LY will be administered subcutaneously for Part A

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 72
LY3298176
Revised Protocol Sections
Note:
All deletions have been identified by strikethroughs.
All additions have been identified by the use of underscore.
The numbering system used for inclusion and exclusion criteria provides a unique number for 
each criterion and allows for efficiency in data collection.
In case an amendment to the protocol adds a criterion, that criterion will receive the next 
available number, regardless of whether it is an inclusion or exclusion criterion.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 73
LY3298176
2.1
Study Schedule Protocol I8F-MC-GPGE Part A
Procedure (Part A)
Screening
Periods 1 and 2
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
21
35 -
37 post 
dose 
period 1
35 -
37 post 
dose 
period 2
≥35 day washout 
between doses 1 
and 2. 
Informed Consent
X
Subject Admission to 
CRU
X
Subject Discharge from 
CRU
X
Subjects may stay 
longer according to 
investigator 
discretion
Outpatient Visit
X
X
X
X
X
X
Investigational Product 
Administration
X
There is a minimum 
of 35 days washout 
period between 
doses for Period 1 
and Period 2.   
Study drug will be 
administered SC
after an overnight 
fast of at least 8 
hours.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 74
LY3298176
2.2
Study Schedule Protocol I8F-MC-GPGE Part B
Procedure
(Part B)
Screening
Treatment
ET
Comments
Days
-28 to -2
-1
1
2
3
4
5
6
7
8
15
35 - 37
≥70 days
PK Samples 
P, 5 
min, 
10 
min, 
30 
min 
1h, 
2h, 
4h,  
8h, 
12h,
24 h, 
36 h
48 h
72h
96h
120h
144h
168h
336
h
X
X
X
All sampling times 
are from start of 
infusion. (0 hr). 
Predose sample must
be collected before 
dose administration. 
If a subject withdraws 
from the study prior 
to completion of 
scheduled PK 
sampling for a given 
period, every effort 
will be taken to draw 
an unscheduled blood 
sample for PK 
assessment.   This 
will not be required if 
a sample has already 
been taken within the 
previous 24 hours.  
For ET, a PK sample 
can be taken at any 
time during the visit 
timed close to the 
immunogenicity 
sample.
Pregnancy Test 
X
X
X
X
All females only.  
Serum pregnancy test 
will be performed at 
screening.  Urine 
pregnancy test will be 
performed at Day -1 
for each period and at 
ET/Follow-up.

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 75
LY3298176
2.3
Study Schedule Protocol I8F-MC-GPGE Part C
Procedure (Part 
C)
Screen
Prestudy
Treatment
ET/Follow-
up
Days
-28 to -2
Before −2
−2
−1
1a
2
3
4
8a
9
10
15 a
16
17
18
22 a
23
24
25
57
≥92
Informed consent
X
Admission to 
CRUc
X
X
X
X
X
X
Discharge from 
CRU
X
X
X
X
Outpatient visits 
to CRU
X
X
X
X
X
Distribution of 
glucose meters, 
test strips, diary, 
and GM training
X
Distribution of 
additional test 
strips, and diary. 
X
X
X
Administer study 
drugd
X
X
X
X
Medical history
X

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 76
LY3298176
Procedure (Part 
C)
Screen
Prestudy
Treatment
ET/Follow-
up
Days
-28 to -2
Before −2
−2
−1
1a
2
3
4
8a
9
10
15 a
16
17
18
22 a
23
24
25
57
≥92
Height and 
weighte
X
X
P
P
P
P
X
Physical 
examination
X
Medical 
assessmentf
X 
P
P
P
P
X
Vital signs 
(BP/PR/T)g
(hours)
X
X
P
X
X
P
X
X
P
X
X
P
X
X
X
ECGh
X
P
P
X
PK sampling
(hours)
P,
8h
24
h
4
8
h
72h
P
P, 
8h
24
h
48
h
72
h
P, 
8h
24
h
48
h
72
h
X
X
Clinical laboratory 
testsi
X
P
P
X
AEs/concomitant 
medications
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Injection site 
reactionsb
P, 
0, 
6h , 
12h 
24
h
P, 
0, 
6h 
, 
12
h 
24
P, 
0, 6,
12
24
P, 
0, 6, 
12
24

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 77
LY3298176
Procedure (Part 
C)
Screen
Prestudy
Treatment
ET/Follow-
up
Days
-28 to -2
Before −2
−2
−1
1a
2
3
4
8a
9
10
15 a
16
17
18
22 a
23
24
25
57
≥92
Pharmacogenomic 
sample
X
Immunogenicity
P
P
X
X
g
Vital signs(BP/PR/T) measurements:  for each dose day: predose, 24 hr, 48 hr, and on or after Day 9284 (follow-up/ET).
h
Single local safety ECGs will be measured at screening, predose Day 1, predose Day 22, predose Day 50 and follow-up/ET to take place
on or after Dday 9284 (follow-up).  
5.1
Overall Design
…
Part A:  Part A is a randomized, 2-period, crossover study in healthy subjects to evaluate the relative bioavailability of 5 mg 
LY3298176, administered as a solution formulation (test), compared to a 5-mg dose administered SC as lyophilized formulation 
(reference).  Treatment sequences and randomization are described in Section 7.2.
Each subject will provide informed consent for study participation, and will undergo a screening examination within 28 days prior to 
enrollment.
In each treatment period, subjects will be admitted to the clinical research unit (CRU) on Day -1.  On the morning of Day 1, following 
an overnight fast of at least 8 hours, subjects will receive a single SC dose of LY3298176, administered according to their assigned 
treatment sequences.  Blood samples will be collected predose and up to 480 hours postdose to measure LY3298176 concentrations. 
At a minimum, subjects will remain in the CRU for 8 days.  The investigator (or qualified designee) will review all available inpatient 
safety data before discharging subjects from the CRU on the morning of Day 8, provided that the subjects are deemed medically fit.  
Subjects may be required to remain in the CRU longer than Day 8, at the investigator’s discretion. The subjects will return to the 
CRU for follow-up visits on Days 21 and 35-37.
…
Part C:  Part C is a randomized, titration study where healthy subjects will be assigned LY3298176 or placebo at a ratio of 3 LY 
subjects to 1 placebo subjects.  The investigator and subject will be blinded to the treatment.  .

I8F-MC-GPGE(a) Clinical Pharmacology Protocol
Page 78
LY3298176
Subjects will receive a treatment regimen of either LY3298176 or placebo to be given as a SC dose on Days 1, 8, 15, and 22, after an 
overnight fast (at least 8 hours). Subjects randomized to LY3298176 will receive a 5-mg dose on Day 1 and Day 8, a 7.5-mg dose on 
Day 15, and a 10-mg dose on Day 22, administered via solution formulation (treatment specifics can be found in Section 7.1).
Each subject will be required to return to the CRU for outpatient visits and for a follow-up visit  on Day ≥92.
For all parts of this study pharmacokinetic sampling and safety assessments, including AE recording, medical assessments, clinical
laboratory tests, vital signs measurement, and electrocardiograms (ECGs), will be performed according to the Schedule of Activities 
(Section 2). 
For each dose after the first dose, the sSubjects will be admitted the day before dosing.  The investigator (or qualified designee) will 
review all available inpatient safety data before discharging subjects from the CRU on Day 3 after the final study procedures, provided 
that the subjects are deemed medically fit. More information is outlined in the Schedule of Activities (Section 2.3). 

PPD
Leo Document ID = 5a9ca3a1-6686-4589-90a3-b6019fc907fb
Approver: 
Approval Date & Time: 22-Jan-2018 19:43:15 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 23-Jan-2018 17:02:53 GMT
Signature meaning: Approved
PPD